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Variability in gene regulation is a fundamental characteristic of biology, allowing 
cellular adaptation in many states, such as development, stress response, and survival. In 
early disease onset, genetic and epigenetic variability permit the formation of multiple 
cellular phenotypes. In cancer, increased cellular plasticity ultimately results in the 
foundation of a tumor with the phenotypic alterations necessary to dynamically adapt, 
proliferate, metastasize, and acquire therapeutic resistance throughout the course of the 
disease. One prominent form of cellular regulation is DNA methylation, an epigenetic 
chemical modification that can alter gene expression. Hypermethylation-induced 
silencing is known to occur early on in tumorigenesis, often in precursor phases of the 
disease. Furthermore, tumors have been shown to undergo epigenetic reprogramming 
throughout progression of the disease. In light of these observations, methylation 
heterogeneity may serve as a novel biomarker for early cancer detection. 
Early detection of cancer remains challenging, as symptoms often manifest in 
later stages and current screening techniques often lack the requisite sensitivity and 
specificity. To maximize effectiveness, routine screening techniques should be 
noninvasive, simple, and unbiased. To this end, liquid biopsies (e.g. blood samples) 
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containing cellular debris, such as tumor-derived cell-free DNA in the plasma, are ideally 
suited towards routine screening. However, detection of tumor-derived molecules in 
plasma is challenging, as they are often rare and may be eclipsed by a high background of 
molecules from healthy cells. Thus a sensitive platform capable of quantifying epigenetic 
heterogeneity could uncover new insights and improve early detection. 
In this dissertation, I present a microfluidic digital melt platform for facile, 
highly-sensitive detection and molecule-by-molecule profiling. The platform is applied 
towards the quantification of epiallelic heterogeneity. Digitization of rare molecules into 
thousands of microchambers followed by parallelized sequencing interrogation through 
high resolution melt enables order of magnitude higher sensitivity than current techniques 
and insight into new intermolecular characteristics. I also demonstrate how this platform 
may be modified to complement and improve the sensing capabilities of existing 
commercial technologies. Finally, I validate the potential clinical utility of this platform 
through detection of methylation heterogeneity in complex clinical samples towards 
noninvasive screening applications. The technical capabilities along with the operational 
simplicity of this platform facilitate adoption by other laboratories and offer potential 
clinical utility. This system may offer new insights into the mechanisms of epigenetic 
regulation in pathogenesis, and potentially improve early diagnosis. 
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EPIGENETICS IN EARLY CANCER EVOLUTION 
Cancer evolution models 
Despite the well-known advantages of early cancer detection, many types of cancer 
are not detected until late stages, when treatment is more challenging and the chance of 
survival is much lower.  Deficiency in early detection may be attributed to both lack of 
understanding of early cancer development as well as inadequate or lack of compliance 
with current screening methods. In order to improve the chances of survival, early 
detection is critical.  There are two avenues of approach to increase early detection rates. 
First, better diagnostic methods should be used that can reliably detect cancer at its early 
stages.  Next, these early biomarkers should be detectable by a simple, routine screening 
method that is inexpensive and reasonably convenient.  
During carcinogenesis, cancers acquire functional characteristics that result in 
unregulated and aggressive growth. Cancer cells undergo malignant transformation 
through a progressive acquisition of genomic aberrations, such as mutations, insertions, 
and deletions, that disrupt the normal regulatory processes of the cell. Numerous studies 
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have uncovered several “driver mutations” which are well-associated with carcinogenesis 
[1], [2].  However, due to the numerous possible driver mutations per cancer and their lack 
of specificity, their diagnostic utility is limited to a small fraction of patients [3].   
A universal characteristic of cancers is genomic instability.  Many tumors exhibit 
intratumoral heterogeneity that can be observed early in carcinogenesis [1], [4]. Most 
models predict that a gradual loss of genomic stability results in the clonal expansion of 
abnormal cells with increased cellular plasticity [4]–[6]. Tumors are believed to follow a 
Darwinian selection model, in which a phenotype eventually arises expressing the 
characteristics of a founder tumor cell that thereby drives tumorigenesis. Further clonal 
expansion gives rise to heterogeneous clonal populations, permitting the tumor to acquire 
many of the hallmark phenotypic alterations that allow cancer to dynamically adapt, 
proliferate, metastasize, and acquire therapeutic resistance throughout the progression of 
the disease [1], [4], [7]–[9].   
 
Epigenetic Regulation 
There are many levels of cellular regulation. Historically, many studies have 
focused on the regulation and aberrations thereof at the genetic level, i.e. the base code of a 
cell’s DNA. However, transcription and translation of the genetic code goes through 
numerous checkpoints and undergoes several modifications before reaching functional 
maturity. Modifications that affect gene expression and are not direct changes to the base 
code are broadly encompassed in the field of epigenetics. Epigenetic changes include 
modifications to the backbone of DNA, to the chromatin, to proteins, or to RNA. Most 
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tumors exhibit hundreds-to-thousands-fold more epigenetic aberrations than mutations 
[10].  
Epigenetic alterations are of particular interest because, unlike genetic alterations, 
they are reversible. Therefore, identifying tumor-driven epigenetic changes holds promise 
for treatment options. In fact, several epigenetic therapies are already clinically available 
[11]–[13]. Results of most treatments are mixed, which warrants further investigation into 
epigenetic mechanisms.   
The most well-studied form of epigenetic modification is DNA methylation, a 
chemical modification that results in an additional methyl group to a cytosine nucleotide 
that is followed by a guanine (CpG), considered the “backbone” of DNA. The 
accumulation of these methylation events, or hypermethylation, can contribute to gene 
silencing and is known to be aberrant in cancer [12], [14], [15]. Interestingly, many tumors 
simultaneously exhibit global DNA hypomethylation [9], [13], [14], [16], indicating that 
methylation has a profound effect on cellular regulation. Recently, studies have found that 
tumors exhibit DNA hypermethylation silencing in the promoter region of tumor 
suppressor genes (TSGs) early in tumorigenesis, prompting several studies investigating 
the use of DNA hypermethylation as biomarkers for early detection of cancer [16], [17].  
 
Epigenetic “Priming” 
Many studies have attempted to uncover the molecular origins of cancer, but the 
foundational events are still elusive and thus are under academic debate. Traditionally, 
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progressive mutations are thought to be the driving events of tumorigenesis. However, 
recent evidence points to epigenetic and methylation aberrations as preceding events to 
driver or passenger mutations, which “prime” the genome for genetic abnormalities [18]. 
Several models have predicted that epigenetic plasticity within chromatin structure, histone 
variants, or miRNAs, can permit or even cause genetic alterations [4]–[6], [16].  
Epigenetic silencing occurs most frequently at earlier, precancerous stages of tumor 
development, and thus can be detected during or even prior to the development of 
precursor lesions [19]–[21]. There is also recent evidence to support that epigenetic 
aberrations such as DNA methylation may occur before genetic alterations (such as 
mutations) [18], [22]. For example, many colon cancers demonstrate overexpression of the 
Wnt pathway [23]. Precancerous lesions were found to have hypermethylation in the SFRP 
gene family, which interact with Wnt pathway receptors [23], [24]. Hypermethylation-
induced silencing of these genes persisted in those lesions that progressed to primary colon 
cancers, whereas none of these lesions possessed any mutations known to be related to the 
Wnt pathway. This suggests that epigenetic silencing predisposed the precursor legions to 
genetic changes associated with clonal expansion, ultimately leading to tumorigenesis [18]. 
This process has been described as “epigenetic sensitization,” in which aberrant epigenetic 
events confer the neoplasticity required for clonal expansion.  
 
Variable methylation 
DNA methylation occurs as a stochastic process, and can thus vary on a patient-by-
patient and even cell-by-cell basis [1], [25], [26]. In fact, the extensive level of 
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“nonsynonymous” alterations, that is those not shared between patients, indicates that 
carcinogenesis many occur via numerous possible pathways [1]. The precise effects of this 
variability and heterogeneity are only beginning to be elucidated. Nonetheless, very recent 
studies have observed that intermediate DNA methylation heterogeneity is predictive of 
metastatic versus localized clones in Ewing sarcoma [27], and that recurrent methylation 
reprogramming of numerous CpG sites across the epigenome in acute myeloid leukemia 
patients occurs throughout the progression of disease [28]. Therefore, further investigation 
into the temporal scope of DNA methylation heterogeneity on a single CpG site basis 
could provide greater insight into tumor cellular reprogramming mechanisms. 
A number of mathematical models have posited that variability in DNA 
methylation patterns starts to increase in adenomous precursor tissue [29], [30]. Using 
meta-analysis of genome-wide methylation data, some studies have shown that measuring 
variance in CpG methylation within a region can serve as a better predictor of disease than 
mean methylation levels [20], [31]. This model corresponds intuitively with our 
understanding of stochasticity in cellular regulation [32]. In one study, hypervariable CpG 
sites were identified in patients three years prior to diagnosis of cervical cancer [30]. 
We propose that analyzing this genetic variability is key to understanding critical 
phases in cancer development and progression (Figure 1.1). By better characterizing 
genetic and epigenetic variability, especially in precancerous phases, we hope to improve 
early detection and diagnosis. 
 
Screening through liquid biopsies 
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Recently it has been found that disease-associated cell-free DNA (cfDNA) can be 
readily found in patient blood plasma. This discovery has opened new avenues for 
molecular diagnostics and prognostics in many diseases [33]–[36]. So-called “liquid 
biopsies” of cell-free DNA (cfDNA) provide several advantages over traditional 
techniques by offering sampling that is noninvasive, heterogeneous, and unbiased, 
prompting increasingly more research into its clinical utility as a diagnostic and theranostic 
platform [37]–[41]. Perhaps the most prominent applications of liquid biopsies are aimed 
at early detection and therapeutic monitoring of cancer, whereby liquid biopsies can 
provide a simple, noninvasive means of sampling DNA derived from throughout the body 
[42]–[44]. In fact, several studies have shown that genetic and epigenetic molecular 
aberrations, such as mutations, copy number variations and DNA methylation correlate 
with tumor evolution and can likewise be found in cfDNA in the plasma [45]–[48].  
Liquid biopsies provide a simple and non-invasive solution to high-throughput 
analysis of patient samples, and are currently in use to monitor therapeutic resistance, 
prognosis, and in screening for biomarkers. However, cfDNA is typically present in 
concentrations of <50ng/ml in the plasma [17], of which fractions as low as 0.01% may be 
tumor-derived strands [42]. Of the tumor-derived fraction, we endeavor to examine the 
methylation heterogeneity among epi-alleles. Consequently, detection of these ultra-rare 
biomarkers requires extremely sensitive and specific analysis techniques. 
 
Methods of Detection 
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To detect methylation patterns of DNA, most techniques rely on bisulfite 
conversion. Bisulfite conversion is a chemical process that converts unmethylated 
cytosines to uracils, thereby creating a sequence change that is representative of the 
template methylation status (Figure 1.2). Methylation Specific PCR (MSP) [49] is a 
technique designed for sensitive detection of locus-specific methylation by using primers 
specific only to fully methylated sequences. MSP and its derivatives, such as SMART-
MSP [50], Methyl-Light [50], and real-time qMSP [51], [52], can detect methylated 
fractions as low as 0.01%,. However, these methods are semi-quantitative and are 
restricted to a single methylation pattern; thus they are impractical for quantification of 
DNA methylation heterogeneity on a single CpG site resolution of rare samples, such as 
those found in a liquid biopsy. 
Molecular analysis has been significantly advanced by techniques such as next-
generation sequencing and digital PCR (dPCR) approaches, namely droplet digital PCR 
(ddPCR), but currently available instrumentation has significant drawbacks that impede its 
applicability for detection and assessment of heterogeneity within rare molecular variants. 
Although sequencing can provide genome-wide sequence information, it has limited 
sensitivity, requiring 2,000-5,000 reads to achieve 0.1% analytical specificity [53], and has 
been shown to have critical shortcomings in sequencing repetitive sequences, such as 
found within CpG islands [54], [55]. Coupled with its complex workflow and high cost, 
these limitations undermine its utility for routine detection of very rare biomarkers. 
In contrast, current dPCR-based methods such Methyl-BEAMing [56] and 
MethyLight ddPCR [57] offer a cost-effective approach to achieve single-copy sensitivity, 
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but also only detect a specific methylation pattern, thus precluding their ability to detect 
and quantitate heterogeneous methylation patterns. An ideal technology should be able to 
combine the advantages of these two techniques, and permit detection of rare and 
heterogeneous DNA patterns (Table 1). 
High Resolution Melt (HRM) is a facile means of assessing sequence variations 
within a target locus by measuring the release of DNA intercalating dye during 
temperature-dependent denaturation. Current commercial dPCR technologies, such as the 
QX200 (Biorad) and Raindance systems, have limitations preventing ready adaptation to 
HRM as a molecular profiling tool, while most non-commercial ddPCR technologies with 
real-time monitoring capabilities require droplet trapping before monitoring, severely 
compromising throughput [58], [59]. Although a number of commercial array-based dPCR 
strategies do exist, namely QuantStudio (ThermoFisher) and Biomark (Fluidigm), they 
lack HRM analysis capabilities, likely due to numerous technical challenges. The limited 
number of in-house attempts have generally been encumbered by significant obstacles, 
such as maintaining thermal control and uniformity throughout the device [60], achieving 
sufficient sequence resolution of a few nucleotides [61], observing dim fluorescence and 
optical noise from small reaction volumes as well as managing stochastic amplification 
variations from digital starting concentrations [62]. These issues primarily stem from 
fundamental limitations in commercially-available hardware or the use of off-the-shelf 




To that end, we designed and developed an assay, termed Discrimination of Rare 
Epi-Alleles by Melt (DREAMing), that interrogates the methylation status of a target 
sequence on a molecule-by-molecule basis, described fully in our previous work [63]. In 
essence, primers were developed for a PCR-type assay that are methylation-preferred, such 
that all epi-allelic variants of the target sequence can be amplified, but methylated 
templates experience an amplification bias, permitting single-molecule sensitivity amongst 
high background DNA. The methylation status is interrogated by DNA Melt analysis, 
which utilizes an intercalating dye to visualize denaturation of ds-DNA during temperature 
ramping. The temperature at which exactly half of the strand is denatured is termed the 
“melt temperature” for that sequence. A single methylation mark, after bisulfite 
conversion, causes the amplicon to denature at a higher temperature due to the increased 
stability of C-G hydrogen bonds and base stacking. In DREAMing, two melt temperatures 
are identified, one for the unmethylated background and one for the methylated variant. 
Due to the digitization of methylated variants, DREAMing represents a quantitative 
analysis of DNA methylation heterogeneity.  
While DREAMing has shown many promising results, its initial implementation 
contains some drawbacks. In principle, DREAMing requires digitization of rare template 
molecules from a bulk solution.  The probability of sample digitization within a well is 
given by the Poisson distribution: 
𝑃(𝑛, 𝜆) = (𝜆𝑛𝑒−𝜆)/𝑛!, 
where 𝑛 is the number of target molecules and 𝜆 is the ratio of positive wells to total wells. 
Thus for the sample to be confidently digitized in a 96-well plate, no more than 9 of the 
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wells should contain the rare target molecule, severely limiting the dynamic range and 
amount of heterogeneity that can be assessed. One possibility to circumvent these issues is 
the use of a larger plate or multiple plates. However, many plates are needed to 
significantly improve the sensitivity, and doing so would be both cost and time-prohibitive 
in reagent consumption and excessively long reaction times. Thus, while the DREAMing 
technique provides a means of evaluating methylation at single-copy sensitivity, the 
unavailability of commercial high-density, HRM-capable instrumentation restricts its use 
for many research and clinical applications. 
 
Overview of dissertation 
The goal of this dissertation is to provide a facile means of detecting and 
quantifying rare and heterogeneous genetic and epigenetic biomarkers in complex samples 
among a high background population. To address this technological gap, I utilized a 
comprehensive bottom-up approach involving both hardware and software solutions aimed 
at addressing these technical challenges. This was achieved by design and fabrication of a 
microfluidic platform called HYPER-Melt (High-density Enumeration and Profiling by 
Melt), consisting of a 4096 nanoliter-well static array microfluidic device and optical-
thermal platform for digital PCR and digital HRM. This high-density array can digitize and 
analyze thousands of individual molecules while limiting reagent consumption to that of a 
typical microtiter well, and provide an absolutely quantitative measure of sequence 
heterogeneity within a target locus throughout a molecular population. The presented all-
in-one chip design is simple to fabricate and use, offers a consolidated workflow, enables 
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rapid and automatic loading and digitization, and is robust to reaction conditions. The 
optical-thermal setup minimizes light scattering and thermal instability, and I introduce a 
post-processing software solution that can be employed to circumvent irregularities 
imposed by hardware limitations thereby permitting reproducible HRM-curve acquisition. 
I incorporated the DREAMing technique into the HYPER-Melt platform to achieve 
highly parallelized assessment of intermolecular methylation variation at single-copy 
sensitivity. The capabilities of this platform were validated through serial dilutions of 
mixed epialleles, with demonstrated detection limits as low as 1 methylated variant in 
2,000,000 unmethylated templates (0.00005%) of a classic tumor suppressor gene, 
CDKN2A (p14ARF). 
Next, I improved the applicability of this platform towards detection of rare 
biomarkers by improving the efficiency of target detection. By implementing a multilayer 
device design and other geometric strategies, flow through the device can be passively 
manipulated to encourage less sample waste. I demonstrated improvements in loading and 
detection efficiency of the platform, resulting in an increased detection efficiency from 
15% to 80%. Furthermore, I describe a novel capture device that can bridge the digital melt 
platform with existing commercial technologies for wider adoption and higher-throughput 
towards large patient cohorts. 
Next, I expanded the capabilities of the platform by enabling the assessment of 
methylation heterogeneity of biomarker panels through development of a dual-probe 
identification scheme that is fundamentally scalable to high degrees of multiplexing. The 
strategy involves ratiometric probe-based identification, incorporating “wobble” bases in 
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order to form methylation-agnostic probes. In addition, I designed and developed a 
multicolor imaging platform to enable rapid target identification, capable of wide-field 
fluorescence imaging of up to four colors. 
Finally, I assessed the clinical utility of this platform as a novel screening tool for 
cancer in complex biological fluids. First, I present a digital assay for and N-myc 
downstream-regulated gene 4 (NDRG4), a tumor suppressor gene that is commonly 
methylated in colorectal cancer. I discriminated methylation patterns of the NDRG4 locus 
in liquid biopsies of healthy and colorectal cancer patients. Next, I present a high-
throughput device for assessment of methylation biomarkers in DNA extracted from Pap 
Specimens in both healthy and ovarian cancer patients. 
Overall, the HYPER-Melt platform allows for extremely sensitive quantification 
and analysis of methylation heterogeneity, and provides multi-dimensional information 
about single molecules that could offer greater understanding of intermolecular variability 
with respect to biological processes such as carcinogenesis and development.  
 
Specific Aims:  
1.   Develop a microfluidic platform capable of ultra-sensitive detection and HRM-
based discrimination of locus-specific sequence modifications. 
1.1  Develop and fabricate a microfluidic device for evaporation-resistant dPCR 
1.2  Design and construct a thermal-optical platform for parallelized, high-resolution melt 
curve acquisition 
1.3  Develop scalable image processing and data analysis pipeline for epiallelic 
discrimination 
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2.   Develop a high-throughput device for efficient sample loading and compatibility 
with commercial instrumentation. 
2.1  Improve microfluidic array to detect and discriminate rare epialleles with minimal 
sample loss 
2.2  Perform ultra-high throughput droplet-based epiallelic discrimination for commercial 
compatibility 
2.3  Develop image segmentation method for real-time droplet analysis 
3.   Develop the capability for assessment of methylation patterns of a panel of 
biomarkers. 
3.1  Demonstrate feasibility of ratiometric fluorescence multiplexing scheme 
3.2  Construct multicolor fluorescence optical instrumentation 
4.   Assess the performance of quantifying DNA methylation heterogeneity in complex 
samples in noninvasive sampling approaches.  
4.1  Detect and quantify methylation heterogeneity of lung cancer markers on circulating 
DNA from liquid biopsies 
















Figure 1.1. Genetic Variability in Tissue Stages 
The genetic variability of cancer is predicted to be highest at precancerous stages, just 
before neoplastic transformation. Therefore, genetic variability may be a candidate 





Figure 1.2: Bisulfite Conversion of DNA 
After bisulfite conversion, unmethylated cytosines are converted to uracil, but methylated 





Table 1. Methylation Detection Methods 
Existing technologies for quantifying methylation are assessed for their sensitivity and 








MOLECULE ANALYSIS WITH DIGITAL 
MICROFLUIDICS 
Microfluidics and Digital Technologies 
Many diseases constitute intermolecular heterogeneity early in development as a 
fundamental means to acquire a selective advantage and proliferate. Notably, even 
infrequent outliers in a population can significantly alter clinical outcome. To better 
understand cellular or molecular populations on a molecule-by-molecule basis requires 
efficient methods of single-molecule analyses. Traditional PCR analysis techniques, such 
as quantitative PCR (qPCR), detect an ensemble measurement of all molecules present in a 
solution. Due to the requirement of standards for quantification, qPCR is only semi-
quantitative. Furthermore, when target molecules exist in a high background, qPCR often 
demonstrates insufficient sensitivity for detection. To perform a true molecule-by-molecule 
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analysis, each molecule must be segregated from the rest of the population. In traditional 
formats, physical separation of every molecule in solution is unpractical and requires 
exhaustive use of reagents and materials. 
The advent of digital microfluidic technologies has significantly improved single 
molecule detection and analysis. Microfluidics enables rapid manipulation of small 
volumes of fluid, thereby facilitating digitization of individual molecules into discrete 
chambers. The ability to compartmentalize samples into droplets for high-throughput 
measurements has greatly improved sensitivity towards detection of rare molecules and has 
opened doors for new insights into single cell and single molecule analyses [64]–[68]. 
Digital analysis provides much higher sensitivity as well as absolute quantification; thus is 
ideally suited for detection of rare molecules and quantification of intermolecular 
heterogeneity.  
Two primary strategies have been proposed for microfluidic digitization of samples 
into small volumes. The first is a static array, in which the fluid is loaded into a low-
aspect-ratio planar device and subsequently divided into individual chambers of sub-
microliter volumes. Alternatively, a volume of aqueous solution may be serially emulsified 
into droplets. Droplet platforms have fundamentally higher throughput potential, but often 
involve more complex instrumentation and are not suited towards real-time analyses. 
Therefore, we focus our attention primarily on the static microchamber strategy to achieve 
real-time molecule-by-molecule profiling.  
There are two fundamental challenges in performing digital PCR (dPCR) on sub-
microliter volumes. First, the small volumes are highly susceptible to evaporation, thus 
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eliminating any signal. Second, the individual reaction chambers must remain robustly 
digitized throughout the reaction to prevent cross-contamination and false positives. 
Several microfabricated chips for digital PCR have been proposed by other laboratories. 
To address evaporation, most of them involve a complicated fabrication step to insert an 
evaporation barrier [69], [70]. While effective, this step complicates the fabrication process 
and is not scalable. To digitize the chambers, most designs utilize mechanically-intensive 
micro-valves for partitioning [69]. Actuated microfluidic valves require increased 
complexity in microfabrication and in device operation. During the repeated fabrication 
step, multiple layers, a valve and a fluidic layer, must be fabricated and aligned. Then, in 
order to actuate the valves, a complex pressure regulation system with multiple inputs and 
outputs is required. Thus, the complex fabrication and operational equipment have hitherto 
significantly hindered adoption of digital analysis techniques.  
Here we present an ultra-thin digital microfluidic device that can accommodate 
high temperatures for extended periods while minimizing evaporation. The device utilizes 
a very simple fabrication scheme, and can achieve a limit of detection of 100 attomolar of 
synthetic target. We show that performing dPCR in this device presents a practicable way 
to quantify rare targets, especially in high background. We demonstrate proof-of-concept 
use of this device to identify synthetic DNA representative of methylated CHFR, a 
potential biomarker for many diseases, in high background. We believe that this simple 
and cost-effective technique will enable wider adoption of dPCR.  
 
Digital Device Design 
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We sought to prevent evaporation without the need for specialized equipment or 
materials and without the addition of layers that may introduce noise in the fluorescence 
signal. The design presented here emphasizes simplicity and avoids such complications by 
utilizing a single fabrication layer, surface-tension partitioning, and readily available 
laboratory equipment. Furthermore, surface tension-based partitioning can be scaled to 
higher density arrays and higher degrees of digitization in future work. 
In our device, sample loss and optical scattering were mitigated by the development 
and use of an ultra-thin fabrication technique (Figure 2.1) to reduce the external volume of 
PDMS. We aimed to fabricate a single pattern layer with <25 µm between the height of the 
pattern and the surface of the PDMS. However, PDMS membranes with a thickness of less 
than ~100 µm experience strong adhesion to a high-aspect-ratio silicon mold, and are 
likely to tear during removal, damaging both the mold and chip. Therefore, our technique 
utilizes a sacrificial PDMS layer to enable imprinted-release of the 60 µm pattern layer 
from the mold without tearing and with high reproducibility. The incorporation of the 
ultra-thin pattern layer, a glass coverslip, and hydration lines effectively prevents 
evaporation during digital PCR [71], minimizes optical interference, and reduces thermal 
deviation, critical to digital melt analysis.  
We next sought to validate this design for its two primary functions: (1) to examine 
whether the new fabrication method sufficiently inhibited evaporation and permitted 
repeated thermal cycling and (2) whether dPCR could be executed on the device.  
 
Device Loading and Evaporation Reduction 
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To provide simplicity in operation, the device utilizes a vacuum-assisted loading 
method followed by surface-tension partitioning to rapidly fill and digitize each 
microchamber. Samples were initially prepared by mixing the reagents and sample off-
chip. The chip undergoes desiccation after fabrication to produce a negative pressure 
differential across the seal of the inlet (Figure 2.2). When punctured, the sample was drawn 
into the device by the force of the vacuum, filling all the wells in less than five seconds. 
Next, an oil-based solution is pressure-driven through the channels. Surface tension 
between the partitioning oil and the aqueous reaction mixture prevents the oil from 
entering the wells, thus isolating and digitizing the template molecules, typically in less 
than 3 minutes. During the PCR reaction, the oil remains pressurized to prevent the sample 
from exiting into the channels. The addition of PDMS in the partitioning oil produces a 
solidified, permanent barrier between reaction chambers that is maintained throughout the 
assay. This technique allows the microfluidic chip to be easily transported for digital melt 
or other analysis without requiring continuous pressurization, and minimizes 
contamination risk by locking the post-PCR samples in place. 
The simple, thin-chip microfabrication technique employed reduced the 
evaporation by an order of magnitude compared to traditional microfluidic devices, which 
overcomes a critical problem for high temperature assays.  Given the same reaction 
conditions, an average of 8% evaporation can be seen per well on the thin chip, whereas 
80% of the reaction evaporates after 60 cycles on a device with standard thickness (Figure 
2.3). This reduction allows for assays that require many cycles, such as high-sensitivity 




After amplification, fluorescent images of the device were acquired from a 
Typhoon scanner. The resultant image was loaded into Matlab for analysis, and the 
average fluorescence of each well was calculated. Each well may be identified by a 
binarization of the grayscale image using an automatic threshold defined by Matlab’s built-
in Otsu method. After processing, plotting the average fluorescent intensity of each well 
produces a bimodal histogram, (Figure 2.4. and an average signal to background ratio of 
10:1 was calculated.  A sample raw image can be seen in Figure 2.4.  The two populations 
are separated by Matlab’s multithresh, and the resulting number of positive and negative 
wells are counted.  The occupancy can be calculated using the equation 
Occupancy = Ntotal * LN (Ntotal/Nnegative ) , 
which assumes a Poisson distribution of positive target throughout the wells of the 
chip, where N is the number of wells.   
The microfluidic device can be used to perform digital PCR across a range of 
concentrations.  The segmentation of the reaction mixture into many wells reduces the 
background such that single events become quantifiable. We demonstrated digital PCR for 
concentrations ranging from 100 – 0.1 fM. The calculated results closely match the 
expected results, as shown in Figure 2.5. A linear fit of the data produces a line with R2 = 
0.999 and a slope of 0.88. These results indicate that the device is incredibly precise, 
although roughly 10% of the target DNA may be lost during sample preparation or during 
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loading. The exact mechanism of loss warrants further investigation. Nevertheless, the 
device achieves sensitive detection and absolute quantification across 4 orders of 
magnitude, down to 0.1 fM. 
 
Discussion 
The development of a robust digital PCR device meets a clinical need for detection 
and quantification of rare genetic events.  Rare mutations or allelic variations can be 
biomarkers of disease.  A device that can quantify these rare events at a digital level can 
allow for early detection of these biomarkers.  We have shown that this microfluidic device 
can quantify rare events, and performs at a robust and reproducible level.   
The implementation of digital microfluidic devices has been limited by fabrication 
and usability. The device presented here requires only simple fabrication techniques and is 
facile to use. Minimization of evaporation is essential for running PCR on a PDMS device. 
This challenge has led most other dPCR devices to employ a complex fabrication method 
[69], [70], [72]. However, we demonstrate a technique that minimizes evaporation without 
any additional use of equipment or materials. In addition, the device presented here does 
not require valves, which necessitate external operating equipment. Rather, it utilizes a 
single layer and a single inlet, minimizing the external equipment required to operate. This 
method may allow wide adoption of dPCR throughout the microfluidic community. 
Further improvements to this system include increasing the limit of detection and 
multiplexing the reaction. Increasing the limit of detection can be achieved by expanding 
24 
the grid of wells, therefore increasing the partitioning of the sample. One challenge in 
incorporating an increased number of reaction wells is the resolution of the imaging 
system. A new, ultra-high resolution imaging mechanism is required in order to increase 
well density without expanding the size of the chip beyond feasible dimensions. 
Multiplexing the reactions on the device becomes less challenging with a high-resolution 
imaging system. Without separation of targets, however, care must be taken to avoid 
nonspecific amplification. Nevertheless, this method of fabrication will drive adaptation 
and progress in the field of digital PCR. 
In this work, we have applied a unique fabrication method to build ultra-thin 
PDMS-based microfluidic devices for dPCR. The method can be adopted in any laboratory 
and obviates the need for complicated processes such as CVD or spin-coating of polymers, 
thereby limiting the time and cost of fabrication, as well as making dPCR technology more 
accessible. Wider adoption of this sensitive and powerful technology may facilitate 




The device consists of five layers, a break-out of which is shown in Figure 2.2A.  
One blank wafer is spun with 15:1 PDMS at 2100 rpm and another blank is spun with 6:1 
PDMS at 100 rpm, which serves as a temporary layer. After baking for six minutes, the 6:1 
blank layer is peeled from the wafer and placed over the 15:1 PDMS. This combination 
bakes for six more minutes to loosely bond the two PDMS layers.  The two bonded PDMS 
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layers are then removed from the wafer and attached to a thin glass slide via O2 plasma 
bonding (15:1 side facing the glass).  After bonding and a five minute bake, the sacrificial 
PDMS layer can be peeled from the chip, leaving just the thin layer. A similar process is 
used to fabricate the thin pattern layer, using 15:1 PDMS for the silanized pattern wafer 
(900 rpm) and 6:1 PDMS for a temporary blank layer (100 rpm). Finally, a thin glass 
coverslide is plasma bonded to the top PDMS layer to reduce evaporation, and an adaptor 
placed over the inlets to interface with tubing.  
Device Loading and Thermocycling 
The PCR reaction mixture consisted of 16.6 mM (NH4)2SO4 ,67mM Tris pH 
8.8,10mM β- mercaptoethanol, 1X ROX Reference dye (IDT), dNTPs (10 mM, 
ThermoFisher Scientific), Forward and reverse primers (0.3 uM, IDT), 0.08 U/µL 
Platinum Taq Polymerase (ThermoFisher Scientific), TAQ Probe (0.2 µM), synthetic DNA 
target (IDT), 0.1% Tween-20 (MilliporeSigma), BSA (New England Biolabs), and water 
(Quality Biological). 1.1 g of uncured PDMS (Ellsworth) mixed at a ratio of 10:1 
(base:crosslinker), and 5 g of silicone oil (100 cst, SigmaAldrich) composed the oil phase.  
The chip undergoes desiccation after fabrication to produce a negative pressure 
differential across the seal of the inlet (Figure 2.2). When punctured, the sample was drawn 
into the device by the force of the vacuum, filling all the wells in less than five seconds. 
Next, an oil-based solution is pressure-driven through the channels. Surface tension 
between the partitioning oil and the aqueous reaction mixture prevents the oil from 
entering the wells, thus isolating and digitizing the template molecules, typically in less 
than 3 minutes. During the PCR reaction, the oil remains pressurized to prevent the sample 
from exiting into the channels. The addition of PDMS in the partitioning oil produces a 
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solidified, permanent barrier between reaction chambers that is maintained throughout the 
assay.  
The device is thermocycled on a flatbed peltier for up to 60 cycles (5 minutes of 
95°C, then 60 cycles of 15 seconds at 95°C and 60 seconds at 60°C).  
Imaging and Image Processing 
Chips are imaged on a Typhoon 9410 Variable Mode Imager at 10 µm resolution.  
Fluorescent images are obtained for both the TaqMan probe (FAM) and the reference dye 
(ROX).  Following detection, the images are imported into Matlab for processing and 
analysis.  A mask is overlaid with the image file. The resulting image contains fluorescent 
data from only the areas of interest. The central pixels of each well are used to measure 
average intensity.  Matlab’s built-in bimodal population separation function, multithresh, is 
used to set a threshold for positive wells. Finally, the number of positive and negative 
wells are counted, and occupancy is calculated assuming a Poisson distribution of reaction 













Figure 2.1. Ultra-Thin Microfabrication 
(A,B) A sacrificial layer was temporarily bonded to the ultra-thin pattern layer by a brief 
bake step. This enabled separation of the joint PDMS layers from the mold without tearing 
of the PDMS. (C) The ultra-thin pattern layer was then O2-plasma bonded to a PDMS-
spin-coated glass slide. (D) After a brief bake step, the sacrificial layer could be removed. 
(E) Finally, a thin glass coverslide and tubing adapter were O2-plasma bonded to the 




















Figure 2.2. Microfluidic device design and operation.  
(A) Breakout of the microfluidic chip. The layers include a PDMS-coated glass slide, 
single PDMS pattern layer, thin glass coverslide, and PDMS tubing adapter for the inlet, 
outlet, and hydration line. (B) A single ultra-thin pattern layer and hydration line 
effectively prevent evaporation through the permeable material. (C) The chip is desiccated 
to produce a negative pressure differential across the inlet. When punctured, the sample 
mixture automatically loads into the chambers. Next, a partitioning fluid is pressurized 
through the channels to isolate the reaction chambers. This figure is reprinted with 







Figure 2.3. Evaporation during PCR.   
Thick chips fabricated using conventional techniques experienced 80% evaporation. In 
contrast, the thin chips only experienced 8% volume loss after 60 cycles of thermal cycling 



























Figure 2.4. Digital PCR Results 
(A) Two overlaid fluorescent images of the microfluidic chip acquired by a Typhoon 
Scanner. The signal image (green) was obtained with 526 nm emission and 488 nm filter, 
and is overlaid with the reference image (red). After Matlab processing, average intensities 
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of each well are obtained (B).  The sample result shown had an expected occupancy of 




Figure 2.5. Digital Quantification Accuracy 
A comparison of expected and measured copies per well.  The expected value was 
calculated based on the stock concentration and dilution in the reaction mixture.  The 







MICROFLUIDIC DIGITAL HIGH RESOLUTION 
MELT 
High-throughput Parallelized Real-time Analysis 
Variability in gene regulation is a fundamental characteristic of biology, allowing 
cellular adaptation in many states such as development, stress response, and survival. One 
prominent manifestation of this variability with respect to human health is Darwinian 
selection within human disease [74]–[76]. From bacterial infections to cancer, diseased 
populations rely on the ability to generate different phenotypes in order to respond and 
thrive in their environment [77]–[80].  Hence, many diagnostic principles rely upon the 
detection of genetic and epigenetic biomarkers, which often consist of minor DNA 
variations that occur even down to the single nucleotide level, such as mutations, deletions, 
frame shifts, and methylation, that provide selective advantage [1], [16], [81]. Likewise, in 
many cases, early detection and diagnosis largely improves the patient’s prognosis and 
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survivability [82]. Although the advent of so-called “digital” analysis technologies has 
furthered the detection of rare modifications in a binary manner, the stochastic and variable 
nature of disease onset and progression could be better understood with a more multi-
dimensional analysis approach. Thus, a system that enables both rare detection and 
population profiling on a molecule-by-molecule basis could greatly aid in detection and 
understanding of disease. 
High resolution melt (HRM) is a facile technique that enables multi-dimensional 
DNA sequence interrogation through measurement of sequence-dependent denaturation 
with a dsDNA intercalating dye, which could be powerful if applied at a digital level. 
Where there exist some commercial technologies for digital PCR, there does not yet exist a 
commercially available system for digital HRM (dHRM). Droplet based technologies, such 
as Biorad and Raindance systems, rely on a single-point readout, which is not suitable for 
real-time monitoring of fluorescence intensity. Fluidigm and Life Technologies are not 
equipped for real-time monitoring and precise temperature control. Furthermore, their 
cartridges utilize micro-valves for digitization, which require complex external machinery 
and operation, and are too costly for disposable use, a requirement to prevent 
contamination in ultra-sensitive analysis. Therefore, they fail to meet several design 
criteria, such as compatibility with available platforms (often require their own 
custom/proprietary equipment), scalability to higher throughput, and sufficient input 
volume.   
To perform highly parallelized copy-by-copy DNA molecular profiling, we 
developed a digital microfluidic platform called HYPER-Melt (High-density Profiling and 
35 
Enumeration by Melt). HYPER-Melt provides a facile means of detecting and assessing 
sequence variations of thousands of individual DNA molecules through digitization in a 
nano-well microchip array, allowing amplification and interrogation of individual template 
molecules by detecting high-resolution melt fluorescence changes due to sequence-
dependent denaturation. As a model application, HYPER-Melt is used here for the 
detection and assessment of intermolecular heterogeneity of DNA methylation within the 
promoters of classical tumor suppressor genes. The capabilities of this platform are 
validated through serial dilutions of mixed epialleles, with demonstrated detection limits as 
low as 1 methylated variant in 2,000,000 unmethylated templates (0.00005%) of a classic 
tumor suppressor gene, CDKN2A (p14ARF). The clinical potential of the platform is 
demonstrated using a digital assay for NDRG4, a tumor suppressor gene that is commonly 
methylated in colorectal cancer, in liquid biopsies of healthy and colorectal cancer patients. 
Overall, the platform provides the depth of information, simplicity of use, and single-
molecule sensitivity necessary for rapid assessment of intermolecular variation 
contributing to genetic and epigenetic heterogeneity for challenging applications in 
embryogenesis, carcinogenesis and rare biomarker detection. 
 
Overview of Epiallelic Profiling by HYPER-Melt 
To achieve high-density molecular profiling, we developed a microfluidic chip and 
associated instrumentation for digitization and interrogation of individual DNA sequences 
(Figure 3.1). The chip is first rapidly loaded with the reaction mix containing rare epiallele 
targets (Figure 3.1A). The chip is then placed on a flatbed heater to perform PCR and 
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HRM. A mirrorless interchangeable lens camera (MILC) acquires images of the entire chip 
at each temperature increment during the melt process (Figure 3.1B). The images are 
processed and analyzed for each reaction chamber to procure a melt curve derivative, from 
which the location of the peak defines the melt temperature (Figure 3.1C). Finally, the melt 
temperatures of all the amplicons were calculated to catalog the initial template 
methylation variants, and compiled in a histogram for quantitative methylation 
heterogeneity analysis (Figure 3.1D).  
Assessment of DNA methylation heterogeneity follows the assay principles laid out 
in our previous report [63]. Briefly, primers were developed such that they provide 
methylation-preferred amplification, in which all epiallelic variants of the target sequence 
are amplified, with a significant bias toward the amplification of the partially and fully 
methylated template molecules. This strategy greatly increases detection sensitivity in the 
presence of a high background of unmethylated DNA. Post-PCR, HRM analysis is 
performed by observing the release of  a DNA-saturating dye (e.g., EvaGreen) during 
temperature ramping [83]. As the temperature is increased, the amplicons denature, 
resulting in a measurable decrease in fluorescence. The temperature at which exactly half 
of the template strands of a particular amplicon become denatured is termed the melt 
temperature (Tm) for that target-sequence. Following bisulfite conversion, methylated 
templates exhibit an increased Tm due to the greater stability of C- versus T-base stacking 
[84].  
In the digital methylation profiling assay, reaction volumes containing both 
unmethylated DNA and a single rare epiallele produce a melt curve with two peaks. The 
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left-most peak pertains to the unmethylated/background DNA. The right-most peak 
corresponds to the rare epiallele, whose methylation density can then be resolved by its Tm. 
Due to the digitization of differentially methylated epialleles, HYPER-Melt provides 
absolute quantitation of all methylated variants and overall methylation heterogeneity. 
The dynamic range of HYPER-Melt and other digital approaches can be described 
by the Poisson distribution: 𝑃(𝑛, 𝜆) = (𝜆𝑛𝑒−𝜆)/𝑛!, where the probability that any given 
chamber will contain 𝑛 copies depends on 𝜆, the average concentration in copies per 
chamber volume. For the principle of HYPER-Melt to apply, each chamber may contain 
no more than one rare methylated variant. By definition, the dynamic range of the device 
scales with the total number of chambers available.  Our proof-of-concept design contains 
4096 wells per microfluidic chip, which facilitates detection and discrimination of over 
1500 heterogeneously methylated variants simultaneously, and can be readily scaled to 
higher quantities. 
 
Design of Thermo-Optical Platform 
To date, one of the greatest challenges preventing other researchers and commercial 
imaging modalities from developing a digital melt platform is the high-throughput imaging 
of a high-density array of sub-microliter volume chambers. The endeavor proved 
particularly challenging because it incorporated the balance of two typically competing 
imaging strategies: small-volume real-time fluorescence monitoring and rapid wide-field-
of-view acquisition. 
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Small-Volume Real-Time Image Acquisition 
Reductions in reaction volume challenge the capabilities of most continuous 
fluorescence monitoring equipment. For example, even commercial instruments, such as 
the Biorad, struggle to produce high-fidelity melt curve results when reaction volumes are 
decreased below 10 uL. Many of the reported real-time fluorescence tracking microfluidic 
chips have a very limited number of chambers, use complex imaging components, do not 
track volumes below tens of nanoliters, and do not have single molecule starting 
concentrations [60], [85]–[87]. Realization of nano-or micro-liter imaging therefore comes 
at the expense of field-of-view. 
Wide Field-of-View 
Large array image acquisition typically requires the use of a microarray scanner or 
another such imaging setup that includes motion and panning of either the camera or object 
of interest and subsequent image stitching in order to image the entire volume at high 
resolution and sensitivity [69], [88]. Another alternative is the use of multiple imaging 
setups [89]. Although these methods can be very effective at end-point detection, there is a 
large time cost involved in real-time imaging. Longer melt durations induce photo-
bleaching, compound the challenge of maintaining thermal uniformity, and decrease 
throughput. Thus, these methods are not suitable for a high throughput digital melt 
platform.  
To achieve a digital melt platform capable of high-throughput imaging of a high-
density array of sub-microliter volume chambers we sought a compromise between two, 
often competing, challenging imaging goals: small-volume real-time fluorescence 
monitoring and rapid wide-field-of-view acquisition.  
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To reduce the effects of noise that can interfere with the melt signal, we developed 
an imaging system capable of measuring thousands of small-volume fluorescence 
variations simultaneously by adapting and optimizing both conventional and 
unconventional imaging components. In order to increase the signal level and minimize the 
Poissonian fluctuation of the nanoliter reaction volumes, a multifaceted optimization 
approach was employed by taking into account the Poissonian statistics and fluorescence 
efficiency of the excitation light and fluorescence emission, respectively[90].  
The probability that a photon reaches a detector can be described by Mandel’s 
Fomula: 
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where 






describes the energy of light hitting detector surface. We focus on the relevant 
components that are controllable, that is T, integration time, W, emitted photon intensity, I, 
excitation intensity, p, the probability of light hitting the detector, A, the size of the 
detector, and r, the working distance. 
Excitation light intensity was increased via incorporation of multiple LEDs to 
provide strong and steady excitation, as well as uniform illumination of the sample (Figure 
3.2). To increase detection probability of the sensor, we utilized a full-frame 36 x 24 mm 
sensor, and optimized the image exposure, ISO, and aperture to balance the signal-to-
background ratio with a reasonable image capture rate.  
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In order to perform on-chip heating, we devised a strategy to address local non-
uniformities and thermal fluctuations that commonly occur in commercial flatbed heaters, 
which can greatly compromise data integrity in highly temperature-critical applications 
such as HRM.  To help reduce thermal variations, we employed thermally-stabilizing heat 
block layers, comprising a flatbed adapter, thermal paste contact enhancer, and a silicon 
wafer to efficiently transfer heat evenly across its surface. The final stabilizing layer is the 
glass slide of the digital melt chip itself. Previous attempts used thin glass slides (0.01mm), 
albeit rapidly conductive, lack rigidity and endured bowing during temperature ramping, 
thus affecting the heat transfer. Therefore, we substituted a thicker, more rigid glass slide 
(1mm) to provide thermal dissipation, improve robustness of the chip handling, and 
achieve more efficient fabrication. The additional thermal stabilization layers increased the 
thermal uniformity of the chip by 172.3% (Figure 3.3B). With the current setup, melt 
curves were acquired in just under 10 minutes with a 0.2ᵒC temperature resolution and a 
Signal to Noise ratio of 5.60 (Figure 3.3C,D). 
 
Validation of HYPER-Melt System 
To assess the intermolecular heterogeneity of the amplicons, images of the entire 
chip were collected during temperature ramping (Figure 3.4). All pictures were aligned to 
the first image using an open-source Automated Image Registration program (AIR) [91]. 
Next, the pixel-space locations of each well were semi-automatically identified by a 
customized Matlab program. The user selects the four corner points of the array image, 
from which a script generates a linearly scaled mask of the array. Misalignment between 
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the chip and camera detector is initially corrected by applying a homography 
transformation of the array mask using the four user-selected points and the generated 
corners. The well boundaries are then shrunk by 10% on each side so that only the central 
mass of the mixture is used for measurement. Finally, each well mask within the grid is 
locally optimized in a 5x5 pixel neighborhood to correct for any additional warping and to 
identify the center of each well (Figure 3.5).  
Once the grid mask is defined, it is propagated throughout each image to obtain the 
fluorescence intensity values from each pixel at each time point. The outlying points from 
each well are removed, and the remaining intensity values from each frame within the 
temperature interval were averaged to obtain a raw curve. Several filters were tested in 
order to ascertain those that best preserved the integrity of the raw data. A combination of 
a low-pass filter and Savitz-Golay filter were found to best remove additional noise while 
still preserving melt information. Next, the derivative was calculated to find the 
temperature at the inflection point of the melt curve termed the “melt temperature” (Tm). A 
digital melt histogram was created that reveals the four distinct populations, which can be 
readily separated by simple thresholding. The methylation density of the original template 
in each reaction volume was then classified by its melt temperature, providing a 
quantitative analysis of methylation heterogeneity on a locus-specific, molecule-by-
molecule basis. 
To assess the capabilities of the HYPER-Melt platform, synthetic targets 
representative of various bisulfite-converted sequences of the tumor suppressor gene, 
CDKN2A (p14ARF), were used as a model system. Four methylation densities were 
42 
analyzed: 0%, 33%, 67% and 100%. The unmethylated (0%) sequence represented the 
background population and was set to 500 copies per nL. The three methylated variants 
were digitized on chip, amplified and identified by HYPER-Melt. The detected number of 
targets for each epiallele was calculated by the number of positive melt-discriminated wells 
while accounting for a Poisson distribution. 
In terms of sensitivity, the platform demonstrated absolute quantitation, as the 
calculated number of copies closely matched the expected number (Figure 3.6). The 
average number of copies detected represents the combined average of the three epiallelic 
variants detected per experiment. The experiments for each of 0, 1, and 10 expected copies 
were repeated. A linear fit produces a slope of 0.91, suggesting that overall, 91% of the 
expected DNA was detected, with an R2 value of 0.97. This discrepancy likely represents 
slight material deformation which deviates from the expected geometry used during 
calculations. The results of this analysis demonstrate that the HYPER-Melt platform 
provides robust, absolute quantitation over five orders of magnitude, attaining accurate 
HRM-based detection down to single copy sensitivity. 
A serial dilution of methylated variants at concentrations of 0, 1, 10, 100, and 1000 
copies/chip was performed in the presence of the 2 million unmethylated epialleles (Figure 
3.7). Representative traces of fluorescence signals from individual wells are shown for 
each test (Figure 3.7B), which were classified by melt temperature via thresholding and 
color-coded by methylation density. Once discriminated by melt temperature, the digital 
result was converted to a methylation density heatmap (Figure 3.7C), which was then 
further quantified and analyzed via a methylation heterogeneity histogram (Figure 3.7D). 
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The master mix was divided such that the same reaction volume was loaded into the chip 
as well as a control benchtop reaction for validation of the PCR and melt success (Figure 
3.7E). 
Overall, the specificity of the HYPER-Melt platform for rare heterogeneously 
methylated epialleles was demonstrated down to fractions as low as 1 in 2 million 
unmethylated copies, or 0.00005%. Even higher specificities are ostensibly achievable by 
the HYPER-Melt platform as it is only limited by the appropriate dynamic range of the 
application.  Heterogeneously methylated epialleles can be readily differentiated with < 
1°C resolution, enabling sequence-specific discrimination of < 4 CpG cites.  
 
Discussion  
The HYPER-Melt platform provides a practical and rapid technique for absolutely 
quantitative assessment of intermolecular variability in DNA methylation levels of a target 
locus with a demonstrated sensitivity of 1 in 2 million background copies at < 1˚C 
resolution (~4 CpG-sites). Its clinical applicability was demonstrated with commensurate 
performance, achieving 20-300X more sensitivity than the gold standard (qMSP), for 
assessment of methylation heterogeneity of NDRG4 in liquid biopsies. HYPER-Melt was 
also compared to more sensitive methods (i.e. ddPCR), where it demonstrated more 
sensitive detection and discrimination of heterogeneous targets (Figure 3.8). There are 
number of key innovations that, when combined, enabled achievement of significantly 
higher HRM sensitivities than previously demonstrated in the literature.  
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The development of a wide-field-of-view imaging platform is critical to achieving 
real-time fluorescence monitoring of such a large array of nanoliter reaction chambers. 
Present commercial digital PCR technologies suffer from a number of key drawbacks and 
are not yet suitable for digital HRM applications.  Droplet-based technologies, such as the 
QX200 (Bio-Rad) and Raindance systems, rely on a single-point readout, which is not 
amenable for real-time monitoring of fluorescence intensity. QuantStudio 12K Flex 
(ThermoFisher) and Biomark (Fluidigm) are not equipped for precise temperature control, 
and the high cost of their OpenArray (ThermoFisher) and Digital Array IFC (Fluidigm) 
cartridges undermines their clinical attractiveness. Many of the reported real-time 
fluorescence tracking microfluidic chips have a limited number of chambers [85], [86], use 
complex imaging components [60], do not track volumes below tens of nanoliters and do 
not demonstrate digital starting concentrations [85]–[87]. Other microfabricated chip 
designs for digital PCR involve a complicated fabrication step to insert an evaporation 
barrier [69], [70], or utilize mechanically-intensive micro-valves for partitioning [69]. 
Multi-layer micro-valve partitioning strategies suffer from complex fabrication methods, a 
limiting valve footprint that reduces scalability potential, and require intricate operational 
instrumentation. Large array image acquisition techniques usually necessitate the use of a 
microarray scanner or similar instrumentation that includes motion and panning of either 
the camera or object of interest, followed by subsequent image stitching or the use of 
multiple imaging setups in order to image the entire volume at sufficient resolution and 
sensitivity [69], [88],[89]. Although these methods can be very effective at end-point 
detection, in real-time imaging they accrue costs of time, photo-bleaching, and thermal 
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instability, thus rendering these methods not suitable for a high-throughput digital melt 
platform.  
In contrast, HYPER-Melt uses readily-available imaging components, such as an 
LED array and a commercial MILC, a predominantly automated processing pipeline, and a 
simple and scalable valve-less microfluidic design to achieve small-volume, wide field-of-
view imaging and high-fidelity melt curve acquisition. Because native current 
commercially available hardware for a thermal-optical platform are not sufficient to 
produce high-fidelity melt curves in a highly parallelized manner, we optimized the 
configuration of readily available components to minimize thermal-optical noise and 
implemented a software solution to extract parallelized single molecule information. A 
common strategy for object detection in fluorescent images is thresholding; however, this 
is susceptible to error due to artifacts and requires very uniform illumination of the sample. 
Alternatively, we introduced a detection technique using a known-mask mapping. This 
technique capitalizes on the known grid design, and offers several advantages. First, a map 
generation script was created to allow for automatic generation based on a few geometric 
user inputs, so that the overall analysis can be universally applied to any grid-based design. 
Furthermore, the localized well-search algorithm relaxes the requirements of illumination 
uniformity due to its restriction to the neighborhood of each well.  
The presented microfluidic solution provides absolutely quantitative sequence 
heterogeneity information at ultra-high sensitivity while maintaining the practicality and 
simplicity necessary for routine use. Notably, recent studies have demonstrated that even 
minor populations of mutated molecules or heterogeneously-methylated epialleles can 
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have direct clinical implications.  For example, intermediate DNA methylation 
heterogeneity is predictive of metastatic versus localized clones in Ewing sarcoma [27] and 
observations of methylation reprogramming on a single CpG site basis in Acute Myeloid 
Leukemia (AML) patients emphasize that molecular heterogeneity plays an important role 
in tumor progression and adaptation to the microenvironment [28]. APC mutations at 
levels as low as 0.01% could be indicative of early colorectal cancer [92]. HYPER-Melt 
provides an enabling platform for similar studies looking to examine the role of rare, 
heterogeneous genetic or epigenetic aberrations on a molecule-by-molecule basis without 
excessive cost and time.  
The capabilities of the HYPER-Melt platform were demonstrated with the 
DREAMing assay [63], designed to detect methylation density of rare molecules amongst 
a background of unmethylated or perceived healthy molecules. The primers were designed 
to introduce an amplification bias towards the rare molecules, allowing single-copy 
detection even in a high background. This approach achieves highly sensitive, absolute 
quantitation of the digitized methylated variants. There are some drawbacks of this 
approach, such as the lack of quantitativeness towards the background molecules due to 
lack of digitization. The Tm corresponds to the number of CpGs that are methylated, which 
may include several permutations depending on the locus. Further analysis would be 
required to identify those exact CpG sites. We previously described how a linear 
regression can be modeled between control points with an in silico model (such as uMelt 
[93]) [63]. Such a model specifies the confidence interval of methylation density at each 
melt temperature and identifies differentiable patterns. A number of factors affect the 
resolution of the DREAMing assay that should be taken into account when choosing a 
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locus, as outlined in our previous manuscript [63]. For example, the methylation density of 
loci that are shorter and have fewer CpGs can be better resolved than longer and denser 
sequences. The resolution can be tailored by designing primers around the region of 
interest. 
The increased sensitivity, as well as the comprehensive methylation density 
information realized by HYPER-Melt, provides the opportunity to set more quantitative, 
multi-parameter threshold values for clinical analysis. Already, DNA methylation has been 
a subject of some treatment strategies which are clinically available [11], [12]. A facile 
means of assessing epigenetic heterogeneity, such as the one presented here, might be 
employed for extending methylation assays from mere detection of the presence of 
methylation to use as a means of real-time monitoring of tumor progression, evolution and 
response to therapy. An underlying premise of precision medicine is that most or all cancer 
cells in a patient share a given targetable genetic (or epigenetic) defect. However, most 
cancers exhibit significant intratumoral heterogeneity, increasing the likelihood of resistant 
clones or subclones [94].  Therefore, there is increasing need for genetic and epigenetic 
profiling of intercellular heterogeneity to identify these resistant clones when applying 
therapeutic regimens. HYPER-Melt provides a simple means of profiling intermolecular 
heterogeneity, and, due to its high sensitivity, may thereby enable identification of even 
rare, potentially-resistant subclones.  
HYPER-Melt is readily extendable to many other applications beyond DNA 
hypermethylation. The ability to fully digitize samples with HYPER-Melt while 
maintaining considerable dynamic range allows absolute quantification for all methylation 
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patterns without bias, thereby enabling the assessment of hypomethylation in CpG-sparse 
loci, which commonly occurs during carcinogenesis [9], [14], [16], [27]. Other 
applications of fully digital HRM include ultrasensitive detection of rare genetic/epigenetic 
variants, including mutation and single-nucleotide polymorphism (SNP) detection [95]–
[97]. Furthermore, digital melt curve analysis also provides considerable advantages over 
digital PCR-based approaches by allowing facile verification of PCR products, a critical 
feature for avoiding false positives in rare target detection and diagnostics. Intermolecular 
variability is of great interest in other applications such as embryogenesis [98], 
carcinogenesis [1], [2], [4], and regulatory circuitry [32], [79], for which HYPER-Melt 
provides a practical and facile means of further investigation.  
There are a few drawbacks in the current platform that are of note. One 
fundamental issue with the microfluidic platform is the potential disparity between sample 
volume and reaction volume. While our chip was specifically designed to achieve 
compatibility with existing bisulfite conversion kits, larger samples would likely require 
incorporation of a concentration method, such as the previously-described, Methylation-
On-Beads technique [99].  The reported benefits of the platform are limited to examining a 
single target in a single sample, which restricts the clinical applications of this platform to 
those with a well-defined, highly specific locus of interest. Alternatively, multiplexing 
could be achieved by splitting samples into subarrays, but would require the use of greater 
sample volumes or additional wells available for digitization to maintain assay 
performance metrics. Furthermore, the current chip is limited in throughput to the 
assessment of a single sample per run. Even though eight samples can be run per day, each 
requires an individual chip, thus the platform has relatively low sample throughput. 
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However, this limitation is similar to many other digital real-time analysis or sequencing 
technologies, in which the sensitivity can be increased by dedicating more of the reaction 
space to a single sample.  
In conclusion, HYPER-Melt provides an all-in-one analysis platform of molecular 
profiling and heterogeneity analysis. The platform allows deep insight at the single copy 
level of any target of interest. Overall, this platform has the potential to detect 
intermolecular variability at ultra-high sensitivity even in difficult and highly-
heterogeneous samples, allowing more comprehensive investigation of the dynamics and 
stochasticity of DNA molecular heterogeneity. Furthermore, the practicality and high 
digitization power of the platform offers a tool for rapid and efficient DNA heterogeneity 
analysis by rapidly interrogating hundreds to thousands of individual molecules in parallel. 
 
Materials and Methods 
Chip Fabrication 
Microfluidic chips were fabricated using standard photolithography and soft 
lithography techniques. To fabricate the reusable master mold, a silicon wafer was 
dehydrated and oxygen plasma treated (Technics PE-IIA) at 80 W for 1 minute. SPR220-7 
photoresist (Microchem) was spun at 2600 rpm for 1 minute and then soft baked at 115⁰C 
for 20 minutes. The wafer was then exposed to the channel pattern using a mask aligner at 
1150 J/cm2 and developed in CD26. After a hard bake at 200⁰C for 6 hours, SU-8 3050 
was spun on the wafer at 2600 rpm for 1 minute. After a soft bake at 95⁰C for 20 minutes, 
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the wafer was aligned to the well array mask, exposed at 300 J/cm2, developed, and baked 
at 200ᵒC for 1 hour. 
Each microfluidic chip was fabricated from this mold using soft lithography and 
our unique ultra-thin ≈80 µm layering technique. The wafer was first silanized to protect 
the photoresist layers. A 15:1 mixture of poly dimethyl siloxane (PDMS, Ellsworth) was 
spun on the pattern at 700 rpm, while a 6:1 mixture of PDMS was spun on a blank wafer. 
Both were baked for 6 minutes at 80ᵒC. The blank, sacrificial PDMS layer was then 
removed and overlaid on the pattern layer, and baked briefly again. A blank glass slide 
(Ted Pella) was cleaned with water and dried. 15:1 PDMS was spun on the glass slide at 
2100 rpm; then baked at 80ᵒC for 6 minutes. Next, the two partially-bonded PDMS layers 
on the pattern wafer could be removed jointly. The pattern PDMS layer and the blank 
PDMS layer on the glass slide were both oxygen plasma treated at 40 W for 45 seconds, 
then bonded. After bonding, the sacrificial PDMS layer was peeled and removed from the 
pattern. Finally, a glass coverslip and tubing adapter layer were oxygen plasma bonded to 
the top surface of the chip. The chip was then baked at 80ᵒC overnight, sealed with a piece 
of thin adhesive tape over the inlet and outlet, and desiccated for a minimum of two hours 
before use. 
Genomic and Synthetic Control DNA 
All synthetic control DNA was obtained from Integrated DNA Technologies (IDT) 
and used at concentrations based on the manufacturer’s specifications. Human male 
genomic DNA (Promega) and Epitect unmethylated control DNA (Qiagen) were used as 
unmethylated control genomic DNA. Enzymatically CpG-methylated HeLa genomic DNA 
(New England BioLabs) was used as a fully-methylated control. Control genomic DNA 
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was bisulfite converted using the EZ DNA Methylation-Lightning Kit (Zymo Research) 
according to the manufacturer’s protocol and eluted into volumes ranging from 12 – 25 µl. 
Post-bisulfite treatment yields were quantified by MethyLight using primer and probe 
sequences for beta-actin recognizing both methylated and unmethylated templates: actin-
sense 5’- TAG GGA GTA TAT AGG TTG GGG AAG TT -3’; actin-antisense 5’- AAC 
ACA CAA TAA CAA ACA CAA ATT CAC -3’, spanning a 103-bp region 
(chr7:5,532,169-5,532,271), and 100nM probe, 5’- \56-FAM\ TGT GGG GTG \ZEN\ 
GTGATGGAGGAGGTTTAG \3IABkFQ\ -3’. Assays were performed using 10X Master 
Mix to yield a final volume of 25 µl and final working concentrations of 16.6mM 
(NH4)2SO4, 67mM Tris pH 8.8, 6.7mM MgCl2 10mM 𝛽-mercaptoethanol, 200µM of each 
deoxynucleotide triphosphate (dNTP) and 0.04 U/µl of Platinum Taq polymerase 
(ThermoFisher Scientific).  Cycling conditions were 95˚C for 5 minutes, followed by 50 
cycles of (95˚C for 5 seconds, 60˚C for 30 seconds and 72˚C for 30 seconds). Standards for 
quantification were created by serial dilution of a 104-bp synthetic target equivalent to the 
bisulfite-converted locus. 
Sample Loading and Digitization 
The PCR and HRM master mixes were prepared to yield final working 
concentrations of 1.66 mM (NH4)2SO4, 6.7 mM Tris pH 8.8, 2.7 mM MgCl2, 1 mM β- 
mercaptoethanol, 300 nM primers (IDT, Table 2), 200 µM dNTPs (Thermofisher), 1X 
ROX (Thermofisher), 0.04 U/µL Platinum Taq DNA polymerase (Thermofisher), 1 
mg/mL BSA (NEB), 0.01% Tween 20 (Sigma Aldrich), and 1X Evagreen (Biotium). This 
master mix was drawn into microcentrifuge tubing (Cole Parmer) using a syringe. Due to 
the desiccation, a negative pressure differential existed inside the microfluidic chip seal. 
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When the needle of the tubing punctured the seal, the sample was drawn into the wells. 
Partitioning fluid, consisting of 5 g Silicone oil and 1 g PDMS (10:1), was then pressurized 
through the channels. Due to surface tension, the fluid did not enter the wells, and served 
to isolate the reaction chambers and digitize the sample throughout the 4096 wells. During 
PCR, the partitioning fluid was pressurized at one end, and sealed at the other. 
Furthermore, the PDMS in the oil solidified over the course of the PCR reaction, 
producing a permanent barrier.  
Digital PCR and Digital Melt 
The chip was then placed on a flatbed thermal cycler (Proflex). Thermal contact 
was ensured by use of FC-40 oil between the glass slide and the heating surface. A PCR 
program then ran for 60 cycles of 95°C, TA (where TA is the annealing temperature for the 
DREAMing primers), and 72°C for 30 seconds each. The annealing temperature, which 
controls the amplification bias of the primers to methylated vs unmethylated targets as 
previously described[63], was optimized for reduced bias to provide more uniform 
amplification of heterogeneously-methylated epialleles (Figure 3.9). The TA was 63°C for 
the p14ARF assay and 57°C for the NDRG4 assay. Next, the chip was removed from the 
heater, disconnected from the tubing, and taken to the digital melt platform (Figure 3.2A). 
The chip was secured to a flatbed heater with tape. The wells were illuminated by an 
expanding blue LED array (Thorlabs). Wide field-of-view imaging captured the 
fluorescence of all 4096 wells simultaneously by use of a Sony ILCE with a 50mm lens 
(Canon), coupled to a green filter (Omega Optical). The chip underwent temperature 
ramping at a rate of 0.1°C/sec from 70°C to 95°C. Images were captured at 1 Hz with a 
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0.8” exposure. An unmethylated control was run before and after each serial dilution to 
verify the absence of contamination.  
Image Processing and Data Analysis 
After collection, the images were aligned to correct for any thermally induced 
movement via an open-source automated program, Automated Image Registration (AIR) 
[91]. The remainder of the analysis was performed with a custom-developed Matlab script 
(Figure 3.5). The user selects the four corners of the chip in order to generate a virtual 
mask outlining the expected well locations. Once generated, the virtual mask was mapped 
to the acquired image via a homography transformation to correct for the non-parallel 
relationship between the signal and imaging surfaces.  Finally, well-by-well 
transformations were performed by locally optimizing the signal over a 5-by-5 pixel 
neighborhood. The overall image contained 4240 x 2832 pixels, yielding approximately 
200 pixels/well.  
Once well locations were determined, the virtual mask was propagated throughout 
all of the collected images and captured the signal intensity of the 200 pixels in each well. 
Fluorescence intensity values within a well at each time point were checked for outliers 
and then averaged. Time points were then sorted by temperature, and each signal within 
0.3°C was further averaged.  Finally, a low-pass and Savitzky-Golay filter was performed 
on each well to produce a melt curve. The negative derivative of this signal was taken, and 
then corresponding peak(s) determined the melt temperature of the amplicon in each well. 
Only the right-most peak is used for discernment in each well to avoid any potential signal 
from heteroduplex formation. Simple thermal calibration was performed by taking 
advantage of the DREAMing assay principles [63], namely a known background 
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population of unmethylated targets, which had a consistent melt temperature and could 
thus be used for inter-experimental alignment.  
MSP/Methylight and ddPCR- MPS/MethyLight 
All MethyLight assays were performed using 10X Master Mix to yield a final 
volume of 25 µl and final working concentrations of 16.6mM (NH4)2SO4, 67mM Tris pH 
8.8, 6.7mM MgCl2 10mM 𝛽-mercaptoethanol, 200µM of each deoxynucleotide 
triphosphate (dNTP) and 0.04 U/µl of Platinum Taq polymerase (ThermoFisher Scientific). 
Each assay was validated by serial dilution to create a percent methylated reference (PMR) 
standard curve ranging from 0.1% to 100% of bisulfite-converted methylated to 
unmethylated control genomic DNA (Promega). MethyLight assay validation results are 
provided in Figure 3.10.  
The MSP/MethyLight assay [50] for NDRG4 was performed with 300nM forward 
primer, 5’- GCG TAG AAG GCG GAA GTT AC -3’, 300nM reverse primer, 5’ – TAA 
ATT TAA CGA ATA TAA ACG CTC GAC C -3’, spanning a 123-bp region 
(chr16:58,463,535-58,63,637), and 100nM probe, 5’- \56-FAM\CGG TTC GTT \ZEN\ 
CGG GAT TAG TTT TAG GTT CGG \3IABkFQ\ -3’. Cycling conditions were 95˚C for 5 
minutes, followed by 50 cycles of (95˚C for 30 seconds, 60˚C for 30 seconds and 72˚C for 
30 seconds) using a CFX96 Touch Real-time PCR Detection System (Bio-Rad) and 
analyzed using the accompanying stock software, CFX Manager. 
The MethyLight and corresponding droplet digital assay for CDKN2A (p14ARF) 
was performed with 300nM forward primer, 5’- TTG TTT ATT TTT TCG TGA GTC GC 
-3’, 300nM reverse primer, 5’ – ACC CTC CGA ATT CGA CG -3’, spanning a 95-bp 
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region (chr9:21,994,226-21,994,310), and 100nM probe, 5’- \56-FAM\ TAC GAC CCG 
\ZEN\ CCG CGA AT \3IABkFQ\ -3’. MethyLight cycling conditions were 95˚C for 5 
minutes, followed by 50 cycles of (95˚C for 30 seconds, 60˚C for 30 seconds and 72˚C for 
30 seconds). MethyLight was performed using a CFX96 Touch Real-time PCR Detection 
System (Bio-Rad) and analyzed using the accompanying stock software, CFX Manager.  
For ddPCR, mastermix was prepared with Bio-Rad Supermix 1X according to Bio-
Rad instructions. Mixed epiallelic targets were diluted to 40, 400, and 4000 copies per 20 
uL, and background unmethylated targets were diluted to 2000000 copies per 20 uL. 
ddPCR was performed in for each dilution in duplicate, with and without the background 
DNA. Droplets were generated with the QX200 Droplet Generator (Bio-Rad), amplified in 
a 96-well plate (Bio-Rad) thermal cycler (Applied Biosystems), and detected via the 
QX200 Droplet Reader. Cycling conditions were 95oC for 10 min, 40 cycles of (94oC for 
30 seconds, 60oC for 1 minute), 98oC for 10 min, at a ramp rate of 2oC/second, as 
recommended by the manufacturer. Thresholding was performed across all reads by the 
proprietary Bio-Rad Software to obtain the copy number detected per reaction volume (20 




















Figure 3.1. HYPER-Melt workflow. 
 (A) The reaction and target mixture, prepared on benchtop, is loaded into the microfluidic 
chip where rare methylated epialleles are digitized. (B) The chip is then placed on a flatbed 
heater to undergo PCR amplification followed by the Melt reaction, in which a MILC 
captures fluorescent images of the array during temperature ramping. (C) The images are 
analyzed to find the melt temperature, which corresponds to the initial template sequence. 
(D) A molecular heterogeneity histogram reveals different populations, which can be 
separated by thresholding and classified by methylation density, providing a quantitative 
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analysis of the molecular heterogeneity of the sample. This figure is reprinted with 












Figure 3.2. Illumination Optimization. 
Several illumination strategies were tested in order to maximize the desired signal, i.e. the 
melt denaturation peak, and minimize isothermal noise. The signal was defined as the 
average peak height of positive wells throughout the chip. The noise was defined as the 
average standard deviation of brightness values within each temperature increment before 
the melt temperature. Counterintuitively, switching from a Laser to LED decreased the 
intra-temperature-increment noise observed during the melt reaction. The final design 


















Figure 3.3. Digital Melt Platform 
(A) The heating components consisted of a commercial thermal cycler with a 96-well plate 
to flatbed adapter and a silicon wafer, to which the microfluidic chip was secured. The chip 
was illuminated by an LED array and filter. Fluorescence detection occurred via a 12 
Mpixel CMOS MIL camera coupled to a filter and focusing lens. (B) Melt temperature 

















Before Thermal Optimization 







 3 x 
Signal (Positive) to 
Background (Negative) 
Noise ≈ 1.51 
Signal Level 














product of a single DNA target. The addition of thermally stabilizing layers and fabrication 
modification of a thicker glass slide greatly improved thermal stability. (C) The positive 
vs. negative signal was characterized by digitally amplifying the target on-chip. (D) The 
signal to noise characterization of the on-chip DREAMing reaction was assessed by 
comparing the average standard deviation of each temperature interval of the overall 
average melt curve to the overall average peak height of positive wells. This figure is 





Figure 3.4. Melt curve acquisition and discrimination by melt temperature.  
(A) Fluorescent images are acquired of the entire chip at each temperature interval to 
visualize denaturation of the amplicons (subset shown). (B) The fluorescence data of each 
well is filtered and plotted against temperature to produce a melt curve. The inflection 
point of the curve is defined as the melt temperature (Tm) of the template sequence. The Tm 
is then used to discriminate the methylation density of the original template epiallele. This 
figure is reprinted with permission from reference [73]. 
  
Unmethylated  















Figure 3.5. Pixel-Space Definition Mapping.  
(A) The user selects four control points from the image acquired by the camera and the 
generated grid image based on the chip mask design which are used to compute the 
homography transformation of the grid to correct for linear misalignment between imaging 
and signaling planes. (B) Next, due to nonlinear nonuniformities in the chip, a local 
optimization of brightness over a 5-by-5 pixel neighborhood is performed to improve 
alignment. (C) The optimized grid captures more fluorescence information than native 





Figure 3.6. Detected vs. expected DNA copy number.  
Mixed epialleles were diluted into a background of 2 million unmethylated templates. 
After amplification and HRM-based discrimination, the detected copy number of each 
epiallele were calculated according to a Poisson distribution. The average epiallelic 
detected copy number was compared to the expected. The array chip demonstrates linearity 





















Figure 3.7. HYPER-Melt analysis.  
(A) HYPER-Melt was used to analyze p14ARF synthetic sequences ranging in copy 
numbers of 0 to 1000 of each epiallelic species in 2 million unmethylated background 
molecules. (B) A subset of melt curve derivatives from each serial dilution, color-coded by 
melt temperature, demonstrate methylation-density-independent amplification of all 
species as well as single-copy sensitivity. (C) The digital heatmap reflects the methylation 
density of the template molecule in each well. (D) The populations of the four epiallelic 
species can be quantified and assessed upon inspection and thresholding of the DREAM 
histogram. (E) Corresponding bulk analysis validates amplification, but demonstrates 
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limited sensitivity due to the low-copy-number methylated peaks being eclipsed by the 





Figure 3.8. Comparison of HYPER-Melt with ddPCR.  
To create an unbiased comparison between HYPER-Melt and other sensitive assays such 
as ddPCR, we designed synthetic targets with degenerate C/T bases in all CpG sites, 
representative of completely random methylation in the primer and target regions for 
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p14ARF. HYPER-Melt was performed following the same protocol as before at target copy 
numbers of 40 and 400 per chip in a background of 2 million unmethylated DNA copies. 
MSP primers were designed for p14ARF, and ddPCR was run for target copy numbers of 
40, 400, and 4000 per run in a background of 2 million unmethylated. We were unable to 
perform the 4000-copy reaction in the chip because it exceeds the dynamic range. (A) 
HYPER-Melt detected ~25-120-fold more copies overall than ddPCR, which is expected 
due to the low probability of the presence of a fully methylated target in each reaction. 
Additionally, HYPER-Melt provides sequence information of each copy detected (B). (C) 
ddPCR was performed for fully methylated targets, both with and without background, to 
validate the MSP assay. (D) Fluorescent readout information from ddPCR. Each dot 
represents the fluorescence from a single droplet. This figure is reprinted with permission 














Figure 3.9. Annealing Temperature On-Chip Optimization. 
Optimization of the methylation bias, defined here as the relative peak height ratio between 
methylated and unmethylated targets, was performed by running DREAMing on-chip at 
multiple annealing temperatures. The optimal bias that still amplified unmethylated DNA 





Figure 3.10. Validation of MSP Assay 
(A) Validation of NDRG4 MSP/MethyLight assay. (B) Validation of CDKN2A 





Figure 3.11. Data Processing Filter Optimization 
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Several filters were analyzed for reduction of noise in the optical signal. Each filter was 
assessed for (A) maintaining the integrity of the raw data and (B) reducing the melt 
temperature deviation within a single population on the device. Overall, a quartic savitsky-

















Figure 3.12. Genomic Validation of HYPER-Melt Platform  
(A) HYPER-Melt analysis of bisulfite-converted EpiTect DNA (Qiagen). Bisulfite 
conversions were performed using EZ DNA Methylation-Lightning Kit (Zymo). (B) 
HYPER-Melt analysis of enzymatically-methylated (Sigma-Aldrich), bisulfite-converted 
DNA. (C) HYPER-Melt analysis of human male genomic DNA from random donors 






Table 2. Assay primers and synthetic targets 
The p14ARF gene sequence is shown above. Primers were designed previously to achieve 
methylation-preferred amplification. The region within the primers contains 13 possible 
methylation sites, of which these 4 were chosen for demonstration of HIPR-Melt analysis. 









HIGHLY EFFICIENT DIGITAL MICROFLUIDICS BY 
PASSIVE GEOMETRIC IMMOBILIZATION 
Disparity in sample-to-analysis volumes 
Liquid biopsies contain a treasure of genetic and epigenetic biomarkers that contain 
information for the detection and monitoring of human disease. DNA methylation is an 
epigenetic modification that is critical to determining cellular phenotype and often 
becomes altered in many disease states. In cancer, aberrant DNA methylation contributes 
to carcinogenesis and can profoundly affect tumor evolution, metastatic potential, and 
resistance to therapeutic intervention. However, current technologies are not well-suited 
for quantitative assessment of DNA methylation heterogeneity, especially in challenging 
samples such as liquid biopsies with low DNA input and high background. We present a 
multilayer microfluidic device for quantitative analysis of DNA methylation by digital 
PCR and high resolution melt (HRM). The multilayer design facilitates high-density array 
digitization aimed at maximizing sample loading efficiency. The platform achieves highly 
parallelized digital PCR-HRM-based discrimination of rare heterogeneous DNA 
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methylation as low as 0.0001% methylated/unmethylated molecules of a classic tumor 
suppressor gene, CDKN2A (p14ARF). 
The HYPER-Melt platform offers a novel method of highly sensitive analysis and 
quantification of methylation heterogeneity suitable for detection of rare biomarkers in 
liquid biopsies [73]. However, while promising, this method, like most array-based 
techniques, analyzes a small percentage of the consumed sample, thereby discarding many 
of the precious disease-derived molecules and their presumed clinical insight [70], [100], 
[101]. Recently, digital technologies have been used to demonstrate that as few as 7 
copies/mL of mutated PIK3CA can indicate therapeutic resistance in breast cancer [102], 
and 2 copies/2 mL of hypermethylated vimentin is present in early stage colon cancer [56], 
illustrating the scarcity of these biomarkers and the need for thorough inspection of plasma 
samples. 
A limited number of existing designs have attempted to address the issue of sample 
throughput, but do not demonstrate performance at high temperature [103], [104], cannot 
guarantee complete digitization [105], or have limited imaging capacity [104]. Therefore, 
there exists a need for a microfluidic device capable of highly efficient sample 
compartmentalization and detection of rare molecules. 
In this study, we present a multilayer microfluidic device for efficient trapping and 
parallelized DNA methylation analysis of single molecules in picoliter-sized chambers. 
The multilayer design facilitates efficient digitization of DNA molecules into 13,000 wells. 
We demonstrate the utility of this digital PCR- high resolution melt (HRM) platform 
through discrimination of partially and fully methylated epialleles of a tumor suppressor 
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gene, CDKN2A (p14ARF) amongst a high background of unmethylated DNA. The ultrahigh 
sensitivity of this platform provides a means for quantitative assessment of DNA 
methylation heterogeneity of rare molecules such as those found in liquid biopsies. 
 
Multilayer geometric manipulation  
To achieve high-efficiency and high-density methylation profiling, we developed a 
multilayer microfluidic chip for digitization and interrogation of individual DNA 
sequences. The device consists of two PDMS pattern layers oriented such that the features 
are in contact. The lower PDMS layer, containing 13,000 750 pL-sized chambers or wells, 
sits below the channel layer, overlapping at the inlets to each chamber (Figure 4.1A). Two 
glass slides sandwich the device, and PDMS adapters provide the loading interface (Figure 
4.1B). The reaction mix rapidly enters the desiccated device through the channels and fills 
the wells (Figure 4.1C). Next, a partitioning oil flows through the evacuated channels, thus 
isolating and digitizing the individual molecules. 
Most array-based technologies suffer from sample loss during loading or 
digitization processes [70], [100], [101]. Previously, our device design comprised of 
parallelized straight channels with perpendicular inlet orientation [73]. During vacuum-
assisted loading, the fluid rapidly filled the channels before saturating the wells, 
disqualifying approximately 89% of the sample for analysis. To minimize loss due to 
channel bypassing, we sought to implement a design that retards flow through the channels 
while maintaining or increasing the fill velocity of each well.  
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The multilayer design promotes efficient loading through two primary mechanisms. 
First, the curved channel design directs fluid to flow towards the walls of the channels 
where the inclined inlets for the chambers are located. The presented curved, single-
channel design constantly redirects flow, increasing flow resistance in the direction of the 
channel. Second, the ratio of the well height (hw) to the channel height (hc) can be tuned to 
adjust the relative force of the vacuum in the direction of the wells (Fvacuum,w) with respect 
to the channel (Fvacuum,c).  
 
 
Modeling and simulation of 2-dimensional device geometries 
To model the effects of the channel and inlet device geometries on the flow profile, 
two-dimensional multiphase fluid simulations of the sample loading into different channel 
and inlet geometries were conducted with COMSOL Multiphysics. First, we compared the 
curved channel to a straight channel under conditions simulating vacuum-assisted loading. 
Initially, the inlet of the main channel was filled with water (aqueous phase) and the rest of 
the geometry was occupied by low pressure air (gas phase). The modeled curved channel is 
a 180° semi-circle. Both channels were 10 mm in overall length and 0.1 mm wide.  
Two physical models were involved in the models: First, the laminar two-phase 
flow, level set model was used to track the interface between two immiscible fluids. It 
solved Navier-Stokes equations for the conservation of momentum and a continuity 
equation for the conservation of mass. The interface position was tracked by solving a 
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Second was the two-phase Darcy's law model which simulated the air permeation 
to the interstices in a porous PDMS substrate medium surrounding the chamber. It solved 
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The simulation results showed an approximately 5-fold retardation in travel 
through the curved channel with respect to the straight channel over the 10 mm path 
(Figure 4.2A). Furthermore, the curved channel demonstrates a more parabolic velocity 
profile than the straight channel (Figure 4.2B). Although the geometry was simplified for 
the purpose of the model, the relationship is expected to be maintained when scaled to 
larger volumes. This result matches our experimental observation that curved channels 
experience slower flow rates. 
Next, we simulated the aqueous sample loading into the chambers at both 
perpendicular and inclined inlet geometries (Figure 4.2C,D). According to the model, 
sample loading from the channel into the chamber took 0.27 seconds and 0.17 seconds for 
90° and 45° inlets, respectively. The relative loading speeds match our observation that an 
angled inlet loaded faster than a perpendicular inlet. However, in the on-chip experiment 
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we observed that loading could take as long as 5-15 seconds. This deviation can be 
attributed to the driving force variation in the sample digitization process. Specifically, 
absolute pressure within the air phase of the chip increases as the sample loads, resulting in 
a reduction in the pressure differential driving the liquid as it moves from the sample inlet 
to outlet. Thus, it takes a shorter time to fill a chamber close to the inlet when compared to 
those located near the outlet. Nonetheless, the essential features of the sample loading and 




Loading efficiency in 2D vs. 3D device 
Experimentally, we sought to quantitatively assess the loading efficiency of the 
multilayer curved channel device (hw = 2*hc) as compared to the identical pattern in a 
single layer (hw = hc). Images were acquired of each device during loading. A single, fixed 
well was chosen for the time course study, beginning at the point the liquid first passes the 
well inlet. At each subsequent time point, the filled area of the well was compared to the 
volume of fluid that had continued along the channel, which we termed the “waste 
volume” (Figure 4.3A). The single layer device had a waste volume of 0.93 µL, 12% of the 
input volume (8 µL), whereas the multilayer produced only 0.34 µL, 4% (Figure 4.3B). 
Furthermore, the multilayer device filled each well ~3 times faster than the single layer, 
resulting in significantly higher loading efficiency of the sample. 
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The multilayer architecture also offers several advantages for partitioning and assay 
performance. The device utilizes a vertical compartmentalization strategy that 
complements the densities of the entrapped materials, namely the reaction fluid (ρfl ≈ 1 
g/mL), the partitioning oil (100 cst silicone oil [Sigma-Aldrich], ρoil = 0.967 g/mL), and air 
(ρair = 0.001 g/mL). Since ρfl > ρoil >> ρair, the partitioning oil drives any remaining 
reaction fluid from the channels down into the wells. Air, which notoriously prevents 
successful high-temperature reactions in enclosed devices, rises up to the channels, and is 
ejected by the partitioning oil (Figure 4.4). The environment is thus robust to amplification 
via high temperature assays such as PCR.   
 
 
Reducing PDMS distortion and misalignment 
Despite the advantages of the multilayer device, achieving reliable and repeatable 
fabrication was nontrivial. PDMS distortion with respect to its mold is a well-known 
challenge in multilayer soft lithography. Several attempts have been made to address the 
issue, namely by characterizing the distortion ratio [106], developing intricate fabrication 
techniques [107], and including tolerances into the design [108]. The presented multilayer 
design requires strict alignment of two peeled PDMS layers, which eliminates simple 
scaling as an option. In order to maintain high efficiency in loading and a high-density 
array footprint, large error tolerances were also not a viable option. Therefore, we 
investigated the relationship between distortion and PDMS height.  
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PDMS patterns of various heights were aligned and compared to the pattern mask 
using a laser microscope (Keyence VK-X100) (Figure 4.5A). For both mold heights, we 
observed a clear trend that smaller PDMS heights led to more predictable and less overall 
distortion (Figure 4.5B). By reducing the PDMS height to 26 µm, the distortion could be 
reduced to ≈0.32%, with a standard deviation of 0.015%. To achieve consistent results 
across layers and thereby minimize misalignment, an ultra-thin soft lithography fabrication 
technique was implemented (Figure 4.6). This ultra-thin technique is simple and obviates 
the need for any additional materials during fabrication. The evaporation potential is 
minimized by reducing the volume of porous hydrogel above the wells. Although 
alignment of the two layers requires a trained user, misalignment can be effectively 
reduced by minimizing the PDMS distortion from the mold.  
 
 
Highly efficient detection of DNA methylation 
To demonstrate the overall detection efficiency of the device, fixed amounts of 
synthetic DNA representative of fully methylated CDKN2A (p14ARF), a well-established 
methylation biomarker for various cancer types [109], were digitized on the device.  8 µL 
of reaction mix were prepared containing a serial dilution of methylated p14ARF from 
≈1000 to 100 copies. Fluorescent images were acquired after PCR amplification to 
quantify the number of detected methylated targets on the multilayer device (Figure 4.7A). 
The absolute copy number detected closely matched the expected amount loaded into the 
chip for each dilution.  
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The results demonstrate an ultimate detection efficiency of 70-80%, and detection 
of as few as 100 copies in 8 µL (Figure 4.7A). The reference channel was used to calculate 
the DNA concentration from the filled wells. The results demonstrate the high accuracy of 
the digital system at 93% (Figure 4.7B). The 7% loss is considered inherent to the system, 
and may occur due to sample preparation or the material properties of the device. 
Therefore, the average loading efficiency of the multilayer device is 80% (Figure 4.7C), 
which is 7 times higher than our previous work.  
The high detection efficiency of this system qualifies it as a suitable method for 
detection of rare molecules in liquid biopsies. The reported average detection efficiency of 
73% includes all potential sources of loss or variability. No system can be expected to be 
100% efficient, as single copies of DNA can be lost in preparation steps, pipetting, freeze-
thaw cycle, etc. Nevertheless, these improvements on loading and detection efficiency are 
important steps in advancing the clinical utility of this digital melt platform. 
 
 
Epiallelic discrimination by digital melt 
A key benefit of the HYPER-Melt platform is the ability to not only detect and 
enumerate target molecules, but also to enable genotyping of a target locus. As shown 
previously [63], in the case of DNA methylation, HRM can be used to readily determine 
the methylation density of each detected epiallele. We used this paradigm to demonstrate 
epiallelic discrimination in the present device by loading and digitizing samples containing 
synthetic oligonucleotide targets representative of bisulfite-converted sequences of 
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heterogeneously-methylated p14ARF epialleles at methylation densities of 33%, 67% and 
100%, as well as an unmethylated (0%) population representing background DNA from 
ostensibly healthy, noncancerous cells.  
Following amplification, the device was taken to the digital melt platform for 
parallelized melt curve acquisition. The negative derivative of the curve was taken to 
determine the melt temperature (“peak”) of each amplicon. Amplification and HRM of the 
unmethylated control DNA at a concentration of 500 copies/nL, or 4 million copies 
resulted in an even distribution of positive wells containing a homogenous population of 
amplicons exhibiting melt centered at 83˚C (Figure 4.8A). Next, 400 copies of each 
methylated epiallele were digitized amongst the 8 million copy background. The melt 
temperature was calculated for each amplicon, and the corresponding methylation density 
was distinguished by thresholding. A methylation heatmap was then generated to provide a 
quantitative metric of the methylation heterogeneity of the sample (Figure 4.8B). 
Representative traces of each epiallelic population demonstrate the high sensitivity of this 
digital melt platform, and a sequence resolution of ≈4 CpG sites. 
The ability to perform HRM-based discrimination enables rare and heterogeneous 
population analysis in an all-in-one platform, for which this is no current commercially 
available alternative. The impact of methylation heterogeneity in cancer and development 
is only just beginning to be elucidated. Several models have predicted that differential 
methylation occurs very early in carcinogenesis [29], [110]. This platform provides a 
simple, low-cost tool for quantification of rare DNA methylation heterogeneity.  
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In conclusion, we presented a multilayer microfluidic device that achieves efficient 
and highly sensitive detection and discrimination of DNA methylation heterogeneity of 
rare molecular populations. The curved channels and multilayer architecture improved 
loading efficiency up to 7x more than our previous design. The digital melt platform 
provides a rapid and facile technique for parallelized sequence interrogation at the single-
copy level, allowing a comprehensive analysis of DNA methylation heterogeneity, 
especially in challenging samples such as liquid biopsies. We hope this technology can be 
applied to potentially improve sensitivity in cancer detection and therapeutic monitoring, 




Molds were fabricated with SU-8 photoresist (MicroChem) via standard 
photolithography. Silicon wafers were dehydrated for at least 4 hours at 200°C, then 
oxygen-plasma treated at 80 W for 1 minute (Technics PE-IIA). For the well layer, SU-8 
3050 was spin-coated at 1800 rpm for 1 min, soft-baked at 95°C for 27 min, and exposed 
at 175 J/cm2. For the channel layer, SU-8 3025 was spin-coated at 1800 rpm for 1 min, 
soft-baked at 95°C for 14 min, and exposed at 150 J/cm2. Both molds were then baked at 
95°C for 5 min, developed with SU-8 developer (MicroChem), and baked at 200°C for 1 
hr. 
PDMS devices were fabricated with an adapted ultra-thin soft lithography 
technique (Fig. S1). PDMS (Ellsworth) at a ratio of 15:1 elastomer base to curing agent 
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was spin-coated on the well and channel pattern layers at 700 and 900 rpm respectively. A 
sacrificial layer of 6:1 PDMS was spin-coated on a blank wafer at 100 rpm. All were baked 
for 6 min at 80°C. The sacrificial layer was then removed, placed on the pattern layer, and 
temporarily bonded by baking at 80°C for 6 min. Both joint layers were then removed 
from the mold. The well layer was bonded to the glass slide by oxygen-plasma bonding at 
80 W for 1 min. Next the wells and channel layers were oxygen- plasma treated, aligned, 
and bonded. Finally, the sacrificial layer was removed, and coverglass and adapters were 
oxygen-plasma bonded to the top surface.  
 
Modeling and Simulation 
Two-dimensional multiphase fluid simulations of the sample loading into a single 
side chamber were conducted with a CFD package (COMSOL Multiphysics® v. 5.2. 
COMSOL AB, Stockholm, Sweden). The model comprised of a laminar two-phase flow 
level set and two-phase Darcy’s law models. Additional parameters and a detailed model 
description are given in the supplementary information (Table 3).The geometric 
parameters, chamber inlet angle and channel curvature, were varied to assess loading speed 
of a single well and fluid velocity along the channel (Fig. S2).  
 
Digital PCR and Melt 
The reaction mix was prepared off-chip to yield final working concentrations of 
1.66 mM (NH4)2SO4, 6.7 mM Tris pH 8.8, 2.7 mM MgCl2, 1 mM β- mercaptoethanol, 300 
nM primers (IDT), 200 µM dNTPs (Thermofisher Scientific), 1X ROX (Thermofisher 
Scientific), 1.2 U/µL Platinum Taq DNA polymerase (Thermofisher Scientific), 1 mg/mL 
BSA (NEB), 0.01% Tween 20 (Sigma Aldrich), and 1X Evagreen (Biotium). The device 
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was sealed with adhesive and desiccated for a minimum of 2 hours to produce an internal 
vacuum. Upon puncturing the inlet, the 8 µL of reaction mix was loaded into the device. 
Next, a partitioning oil, comprised of 5 g of 100 cst silicon oil and 1 g of 10:1 PDMS was 
pressurized through the channels to digitize the chambers. The device was placed on a 
flatbed heater (ThermoFisher Scientific) to undergo dPCR (5 min at 95°C, followed by 60 
cycles of 30 s at 95°C, 30 s at 61°C, and 30 s at 72°C). Digital melt curves were acquired 
on our previously described digital melt platform[73], in which fluorescent images were 
captured by a Sony ILCE MILC at 1 s intervals during a thermal ramping at 0.1 K/s. 
 
Imaging  
End-point fluorescent images were captured by a Typhoon Scanner (ge 
Amersham). Two channels were detected: excitation and emission of 488 nm and 526 nm 
for the Evagreen signal as well as 532 nm and 610 nm for the ROX reference signal. Post-
processing of the images was performed in Matlab. RGB fluorescent images from melt 
acquisition were converted to grayscale. A binary mask image was aligned with the 
reference image to identify the pixel-space definition of each well following our previously 
outlined procedure[73]. Positive wells were identified by thresholding of the Evagreen 














Figure 4.1. Multilayer Device Geometry 
(A) The device consists of 2 PDMS layers sandwiched between glass slides. The curved 
channel sits above the wells. (B) The device is fully loaded with dye from a single inlet 
and semi-circle bifurcation. (C) Reagents are loaded into a vacuumed device, filling the 
wells. Oil is pressurized through the channel for partitioning and to eject excess air. This 
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Phase Flow, Level 
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Laminar Two-
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Fluid 1: air. Fluid 2: 
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dynamic viscosity 
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Pressure P0= 0, 
Suppress backflow 
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Kr1=0.2, Kr2= 0.01 
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0.01atm N/A N/A 
Mesh 
1849 domain & 
207 boundary 
elements 
2144 domain & 
219 boundary 
elements 
7256 domain & 
1458 boundary 
elements 




method generalized-alpha generalized-alpha generalized-alpha generalized-alpha 
Time step size 0.01s 0.01s 0.1s 0.1s 
Time 10s 10s 10s 10s 
 
Table 3. Parameters involved in the two-dimensional multiphase fluid model of the sample 





Figure 4.2. Simulation Results 
(A) COMSOL simulation results of sample loading in 180° curved vs. linear main 
channels with same length by two-dimensional water-air multiphase flow CFD analysis. 
(B) Aqueous sample velocity profiles of each channel geometry after the channel was 
filled with the aqueous sample. COMSOL simulation results of sample digitization by two-
dimensional water-air multiphase flow CFD analysis before (t0), (C) Straight (D) 45° 
inclined chamber filling; shown are the color contours of the water volume fraction 
ranging from blue = air to red = water (refer to the color legend) and the water/air 
interface. The vectors show the flow velocity in the whole geometry. This figure is 







Figure 4.3. 2D vs. 3D Comparison of Fill Rate and Waste Vlume 
(A) Continuous images were acquired during loading of dye into a single layer and 
multilayer device. A timer starts when the dye first passes the single observation well, and 
ends when the well is fully filled. (B) The fill rate, time to fill a single 750 pL well, is 
much faster for the multilayer device. The waste volume, volume of liquid that is in the 
channels past the observation well at the time of fully filled, is lower for the multilayer 




Figure 4.4. Loading volume vs. Reaction Success 
Loading and partitioning of single-layer microfluidic device. The device has a capacity of 
4 µL and was loaded with 8 µL. Air entered the chip after loading and resides in the wells 
after partitioning. This air caused significant evaporation and sample loss during heating 
steps. (B) Loading and partitioning of multilayer device. The device was loaded at less 
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than full capacity to minimize loss. Air collects in the channels and is removed by oil 


















Figure 4.5. PDMS Warping vs. Thickness 
(A) The PDMS pattern was aligned against the mask to measure the percent distortion. (B) 
The distortion was compared at different PDMS thicknesses for molds of two different 
































Figure 4.6. Multilayer Fabrication Protocol 
Ultra-thin layers of PDMS were spun on each pattern mold, and removed by temporary 
bonding of a sacrificial layer. The two patterns were then oxygen-plasma treated, aligned, 
and bonded. Finally, a coverglass and adapters where oxygen-plasma bonded. This figure 






Figure 4.7. Loading and Detection Efficiency 
(A) Fluorescent images were captured of the positive wells for a dilution of methylated 
p14ARF. The reference dye was used to detect loaded wells, and a threshold was applied to 
calculate the total number of amplified DNA copies. (B) After accounting for the unloaded 
wells, the calculated copies per µL was compared to the expected. The relationship is 
linear with a slope of 0.93. (C) On average, 73% of the template molecules are detected. 
7% of the sample is lost during preparation or storage, resulting in an estimated loading 





Figure 4.8. Epiallelic Discrimination 
(A) Unmethylated sequences of p14ARF were amplified and discriminated by melt. (B) 
Epialleles at three defined methylation densities were loaded into the device along with the 
unmethylated background. All patterns were then amplified and discriminated by melt 







DROPLET DIGITAL HIGH RESOLUTION MELT  
Overview of Droplet technologies 
Clinical adoption of new technologies requires both strong analytical capabilities as 
well as sufficient throughput for patient or sample load, a factor that is often overlooked in 
development of microfluidic platforms. Despite advances in microchamber real-time 
analysis platforms, such static arrays will always be limited in throughput compared to 
droplet technologies. The ability to serially generate as many droplets as needed provides 
for fundamentally unlimited sensitivity and much higher throughput. Thus, many 
laboratories are realizing widespread adoption of commercial droplet digital PCR (ddPCR) 
platforms.  
Droplet microfluidic platforms have greatly enhanced the throughput and 
sensitivity of single-molecule and single-cell analyses. However, real-time analyses of 
individual droplets remain challenging. Most droplet microfluidic platforms have 
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fundamental drawbacks that undermine their utility toward applications that rely on real-
time monitoring to identify rare variants, such as bacterial persistence, drug discovery, 
antibody production, epigenetic biomarker analyses, etc. We present a platform for high-
density droplet trapping and real-time analysis with 100% loading and trapping efficiency 
at a packing density of 110,000 droplets per in2. To demonstrate real-time analysis 
capabilities, we perform digital PCR and parallelized digital high-resolution melt curve 
acquisition on droplets to discriminate methylation levels of a tumor suppressor gene, 
CDO1, on a molecule-by-molecule basis. We hope that this platform, which is compatible 
with a large range of droplet sizes and generation technologies, may facilitate high-
throughput real-time analyses on a molecule-by-molecule or cell-by-cell basis of 
heterogeneous populations.  
Droplet platforms have been used to detect and analyze nucleic acid and protein 
biomarkers as well as single cells with drastically higher sensitivities than bulk methods 
[64], [112]–[116]. Furthermore, with advances in droplet microfluidic technologies, 
commercial platforms like BioRad QX200 ddPCR and RainDance RainDrop have become 
turnkey tools for a wide range of clinical applications, such as copy number variation 
[117]–[119], biomarker detection [120]–[123], gene expression analysis [124]–[126], and 
pathogen detection [127], [128]. 
Despite their tremendous advantages in sensitivity and throughput, most existing 
droplet platforms rely on sequential measurements of each droplet and its assay reactants at 
a single predetermined time point (“endpoint analysis”) [129]–[132]. This limitation 
precludes their utility in biological assays that rely on or benefit from time-resolved 
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measurements of reactants (“real-time analysis”), such as molecular profiling using 
melting curve analysis [60], [63], [73], [111], [133]–[135], cell growth monitoring [136], 
[137], and enzyme kinetics observations [58], [138]–[140]. 
For effective real-time analysis of individual droplets, it is advantageous to 
immobilize the droplets such that they can be easily monitored over the course of the 
assay. However, previous attempts at developing such a real-time droplet analysis platform 
have resulted in a tradeoff, in which there is a reduction in either throughput or droplet 
capture efficiency. To ensure trapping of many or most of the droplets in a reaction, some 
methods directly generate droplets into a chamber or reservoir for reaction and analysis 
[59], [103], [141]–[143]. However, once loaded, these devices are sealed and droplet 
generation halted while all required reaction steps are performed in the chamber. 
Therefore, these “on-chip” methods are inherently limited in throughput, as the entire 
device is restricted to a single run of a single condition or sample, especially for multistep 
assays that contain time-consuming reaction or incubation steps. Even with multiple 
devices, the number of reactions or samples that may be parallelized is constrained by the 
two-dimensional surface area of commercial heaters. Moreover, the footprint of these 
chambers may be inefficiently utilized, as they retain the immiscible oil phase used in 
droplet generation. 
In contrast, trapping strategies that are fundamentally compatible with “off-chip” 
droplet production allow high-throughput parallelization of time-limiting reaction steps on 
conventional 96- or 384-well plates before subsequently attempting to capture the droplets 
in an array/chip for analysis. These methods potentially enable simultaneous assessment of 
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multiple reactions, a range of reaction conditions, or large patient/sample cohorts for time-
limiting reaction steps in a high-throughput manner that is favorable for translational 
potential. In addition, the throughput of subsequent real-time analyses can be further 
enhanced by incorporating multiple trapping units on a single device. However, current 
“off-chip” trapping designs have poor capture efficiencies, only capturing and analyzing a 
small percentage of overall droplets [58], [136], [144]–[146], as a large number of droplets 
tend to bypass the storage chambers and are lost when loading the array.  
Ultimately, loss in either throughput or droplet capture efficiency undermines the 
utility of current platforms towards clinical analyses of rare molecules or biomarkers and 
applications that require real-time monitoring to identify extremely rare variants, such as 
bacterial persistence [147], drug discovery [148], directed evolution [149], antibiotic 
resistance [150], and circulating biomarker analysis [63], [73], [110], [111], [133]. To 
overcome this tradeoff, we have developed a real-time droplet platform that enhances the 
overall throughput of droplet real-time analyses by maximizing space utilization, 
operational flexibility, and capture efficiency.  
Herein we present a microfluidic platform with 100% loading efficiency for high-
density droplet trapping and real-time monitoring that is universally compatible with other 
droplet systems. The platform consists of a microfluidic droplet trapping device and a 
thermal-optical platform for parallelized real-time analyses across a wide range of 
temperatures. The trapping device employs a simple, passive immobilization strategy that 
is fundamentally compatible with any droplet size, and therefore is congruent with existing 
commercial droplet platforms.  
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Highly efficient loading and capturing of droplets via pseudo-sieve 
The presented platform enables high-density trapping and immobilization of 
droplets for real-time monitoring and detection of rare molecules or variants.  The platform 
consists of two main components: (1) the droplet trapping and immobilization device, 
which loads and immobilizes droplets at 100% efficiency by means of a sieve-like floor, 
and (2) the thermal-optical imaging platform, which acquires fluorescent images of all 
droplets within the device at specified temperatures. We implement this platform to 
perform high resolution melt (HRM) analysis for detection and discrimination of rare 
methylated biomarkers.  
We previously developed a technique termed DREAMing, Discrimination of Rare 
EpiAlleles by Melt, as a facile means of detecting various methylation patterns on a 
molecule-by-molecule basis amongst high background [63]. Briefly, the technique utilizes 
methylation-preferred or methylation-agnostic primers to amplify all bisulfite-converted 
methylation patterns of a given locus at single-copy sensitivity. Next, the sequences are 
discriminated by HRM by observing the sequence-dependent release of a DNA 
intercalating dye during thermal ramping. However, this technique performs quasi-digital 
analysis via conventional multiwell plates with limited dynamic range of detection and 
sensitivity, thereby undermining its practicality for clinical use. To address this, we 
developed a microfluidic digital array platform called HYPER-Melt in which we 
implement this technique in a high density array of nanowells [73]. This microfluidic 
digital array platform enables detection and discrimination of methylated variants at 
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frequencies as low as 0.00005%. We then further improved the platform by increasing the 
loading efficiency from 12% to 80% [111]. However, this on-chip integrated system 
suffers from low throughput due to minimal parallelization of the time-consuming PCR 
step (three hours) required before dHRM analysis (five minutes). 
Therefore, we sought to implement this technique on a digital droplet platform in 
order to significantly improve performance in terms of sensitivity and throughput. Whereas 
the array-based device is limited to performing ~4 to 6 PCR reactions in parallel on a 
single thermocycler, a commercial ddPCR system such as the BioRad QX200 may digitize 
as many as 8 samples into droplets at once, and can perform the time-limiting PCR step on 
as many as 96 samples simultaneously. By incorporating off-chip PCR thermocycling with 
a multi-module droplet trapping device and HRM platform, the system can realize both 
higher loading efficiency and much higher throughput.  
To perform droplet digital HRM (ddHRM), we compartmentalized the reaction mix 
into droplets by flow-focusing. Droplets for each sample to be analyzed were loaded into a 
well of a 96-well plate and amplified by PCR in parallel on a thermal cycler. Next, droplets 
were loaded into the trapping device, and melt curves were acquired from each amplicon 
via the thermal-optical platform. After analysis, a population profile of various methylation 
levels was generated for each sample. 
 
Device Architecture 
100% Efficient Loading and Trapping Mechanism 
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The high-density packing device consists of a glass microscope slide at the base 
and two PDMS layers, an upper droplet chamber and a lower pseudo-sieve floor (Figure 
5.1A). Up to five modules may be assembled in parallel onto a single glass slide as needed. 
Within each module, the pseudo-sieve layer is comprised of tightly spaced eight-sided 
polygonal posts (Figure 5.1B). The intermittent top surfaces of each post are defined as the 
“floor” of the droplet chamber. The continuous surface at the bottom, between each post, is 
considered the “basement” of the device. A “highway”, or space without posts, runs 
between columns at approximately each third of the device to evenly space the droplets 
and relieve pressure. 
The grid-like arrangement of the posts creates an array of gaps in the floor of 
diameter dg between the corners of each post. Upon entering the chamber, the height of the 
ceiling (hc) is less than the spherical height of each droplet, such that droplets are under 
slight compression between the ceiling and the floor (Figure 5.1C). Droplets favor 
placement over the gaps due to the decrease in surface tension [145]. The tight spacing 
between posts prevents droplets from escaping below the chamber into the basement of the 
device, whereas any excess oil between droplets may pass between the posts, through the 
basement, to the outlet of the device (Figure 5.1D). 
Droplets are pressure-loaded into the device inlet with a syringe pump (Figure 
5.1E). Upon reaching the droplet chamber, droplets self-assemble into a grid-like 
arrangement over the posts. Once reaching the end or side walls of the chamber, droplets 
are unable to escape, thereby demonstrating 100% efficiency in loading. Excess space 
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occupied by oil in the droplet chamber can be removed through the basement to achieve 
100% efficiency in trapping at a packing density of 110,000 droplets per in2 (Figure 5.1F). 
Scalable Droplet Capacity 
In most single-point disseminating loading mechanisms, wherein droplets are 
propelled by pressure-driven flow, a pressure gradient develops as more droplets 
accumulate downstream and offer resistance. Since the pressure is greatest at the inlet, this 
limitation is known as “back-pressure.” Excess back-pressure is a common problem in 
many microfluidic trapping systems which limits the total amount of droplets that can be 
loaded while maintaining droplet stability [139]. In earlier generations of the device 
design, we observed increased compression of droplets due to pressure during filling of the 
final corners of the device, especially at the center regions on each end (Figure 5.2A), 
which could compromise droplet integrity. 
To address this, we implemented “highways” to reduce back-pressure and to 
facilitate even distribution of droplets throughout the device chamber during loading. The 
highways run through the initial 75% of the device, whereupon they cease to ensure 
trapping at the distal end. After implementing highways between each third of the device, 
droplets were observed to exhibit uniform, minimal compression throughout the device 
(Figure 5.2B, Figure 5.3). Therefore, the device design is fundamentally scalable to higher 
droplet capacities. 
 
High-throughput real-time melt curve methylation profiling from droplets 
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Although the key goal in developing this device was to provide real-time 
monitoring capabilities, the device and imaging platform may also be utilized for highly 
accurate quantification and detection of rare molecules. While current commercial 
platforms may include separate fluorescent readout instrumentation, they provide no means 
of visual inspection and droplets are irrecoverable after analysis. Droplets in the high-
density packing device may be quantified with any fluorescence platform as well as bright-
field microscopy to allow for visual inspection of the droplets. 
To validate the accuracy of the system, a serial dilution of synthetic DNA, 
representative of bisulfite-converted 100% methylated CDO1, was partitioned into 500 pL 
droplets, amplified in a 96-well plate, and then loaded onto the trapping device. The device 
was placed on the thermal-optical platform to acquire a single wide-field fluorescent 
image. The droplets were segmented in ImageJ, whereupon the number of positive droplets 
was calculated from the Poissonian occupancy equation. The assay was also cross-
validated by performing the same protocol in bulk and with the Biorad QX200 system 
(Figure 5.4). 
The expected occupancy of the synthetic target ranged from 11% to 0.04%. The 
calculated vs. expected occupancies are shown in Figure 5.5 (log-log). The lower 
occupancies were repeated thrice while the higher occupancies were tested once. A linear 
regression curve was fit in Matlab, producing a slope of 0.98 with an R2 of 0.99. These 
results demonstrate the utility of this platform for highly accurate droplet quantification, 
and provide a simple alternative to complex commercial droplet readers. 
System Versatility  
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Due to the wide range of applications utilizing droplet technology, a fundamental 
aspect of the device design was versatility in droplet generation platforms and in droplet 
size. Therefore, we assessed the loading performance of our device across a range of 
common droplet volumes. Devices capable of producing 100 pL, 600 pL, and 1000 pL 
droplets using flow-focusing discretization were designed. The devices included geometric 
modifications of the flow-focusing nozzle used in devices we have previously developed 
[151]–[153]. Droplets were also generated using the BioRad QX200 platform and assessed 
for compatibility with the trapping device and real-time system. The device demonstrated 
100% efficiency in loading of droplets ranging from 100 pL to 1 nL (Figure 5.6).  
The increasing number of applications of droplet technology may be attributed to 
the increased availability and reliability of commercial droplet platforms [154], such as 
BioRad’s QX200 droplet system and RainDance’s RainDrop Plus platform. In addition, 
increased research into surfactants and other droplet stabilizers [65], [100], [149], [155] 
has propelled the development of microfabricated droplet generation systems [65]–[67], 
[156]–[158]. With this device, we demonstrate loading and analysis of droplets generated 
by both our microfluidic droplet generation device as well as droplets generated by the 
Biorad QX200 system. By integrating this device with other droplet systems, real-time 
analysis of droplets can be achieved without compromising throughput. 
 
Droplet Immobilization and Real-time Imaging 
For time-lapse analyses of densely-packed systems, droplet immobilization is 
critical to reduce the computational burden of droplet identification and ensure analytical 
108 
confidence. We demonstrate droplet immobilization on the device by evaluating the 
position of post-PCR droplets in time-lapse fluorescent images during thermal ramping. A 
mastermix was prepared with synthetic DNA representative of bisulfite-converted 
methylated CDO1, from which 600 pL droplets were generated in a flow-focusing device. 
After ddPCR in a 96-well plate, the droplets were loaded into the trapping device. The 
device was sealed on both ends and placed on the thermal-optical platform.  
Fluorescent images were acquired of the droplet trapping chamber during thermal 
ramping (Figure 5.7). A grid is superimposed over a sub-region of the device to illustrate 
the relative position of droplets between frames. Even at high temperatures, droplets 
remain immobilized and stable, validating the robustness of the trapping mechanism. This 
simple immobilization technique does not require any external equipment, and provides a 
facile means to maintain discretization of signals from adjacent droplets in densely-packed 
high-throughput systems. 
 
Parallelized Droplet Digital High Resolution Melt (ddHRM) 
We illustrate the potential utility of this platform towards analysis of heterogeneous 
populations by performing droplet digital High Resolution Melt (ddHRM) to discriminate 
molecule-by-molecule methylation patterns of bisulfite-converted DNA. Synthetic DNA 
molecules representative of bisulfite-converted 0%, 50%, and 100% methylated CDO1 
were digitized into 600 pL droplets. Droplets were then aliquoted into a 96-well plate and 
amplified in a thermal cycler following a standard PCR protocol with methylation-
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preferred primers as previously described [63]. Next, droplets were loaded onto the droplet 
trapping device and placed on the thermal-optical platform for HRM analysis. 
Wide-field fluorescent images of the droplet trapping region were acquired at 0.3°C 
intervals during temperature ramping. To extract information from each individual droplet, 
the images were first segmented in ImageJ (Figure 5.8) to identify the position of each 
droplet (Figure 5.9A). Next, an automated Matlab script extracts the fluorescent 
information from each droplet at each temperature interval to generate melt curves (Figure 
5.9B). The peak of the negative derivative of each curve defines the melt temperature (Tm) 
of each sequence. A digital melt histogram then displays the Tm of each amplicon, which 
clearly depicts three distinct populations. The methylation density of each droplet can then 
be classified by its Tm, providing a quantitative population profile of methylation 
heterogeneity.  
The system exhibits a high signal-to-background ratio of 1.9, and analysis of 
surrounding negative droplets shows minimal change over the course of HRM acquisition 
(Figure 5.10). Fluorescence leakage or diffusion between droplets was not observed, 
however, these system characteristics should be assessed for each application, as different 
assays, reaction mixes, or oil compositions may result in different behavior. 
DNA methylation is one of the most-commonly studied epigenetic alterations in 
cancer progression [8], [11], [15], [16]. Recent studies have shown that variable 
methylation levels within a locus correlate with disease progression [27], [28]. 
Furthermore, many models predict that methylation levels are highly variable early in 
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carcinogenesis [29], [31], [110]. We hope that this device and platform will enable further 
study into the effects of variable methylation on cancer etiology.  
We developed a high-density droplet trapping device and thermal-optical platform 
for time-lapse analyses of up to 30,000 droplets in parallel. Single molecules of DNA were 
compartmentalized, amplified, and quantified at high accuracy across three orders of 
magnitude at concentrations as low as 0.8 copies per µL. We demonstrated the utility of 
this platform by profiling variable methylation levels of a tumor suppressor gene (CDO1) 
with ddHRM. To our knowledge, this represents the first demonstration of ddHRM.  
The pseudo-sieve functionality of the droplet chamber enables 100% loading and 
trapping efficiency, thus the device is highly suitable for analysis of rare molecules or 
variants. The simple, passive immobilization strategy is compatible with droplets of 
different sizes and many readily-available imaging modalities. We demonstrated effective 
mitigation of back-pressure, indicating that the design is readily-scalable to higher droplet 
capacities and throughput.  
There are aspects of the device design that could see readily-achievable 
improvements. First, droplets have the potential to be recovered by reversing the direction 
of flow in the device. Second, the throughput may be further increased in both sample 
number and droplet capacity. Within a chamber, although the scaling potential is not 
expected to be limited by back-pressure, a larger droplet chamber with a high aspect ratio 
(w/h) may experience sagging during fabrication. This could be simply addressed by 
incorporating support posts throughout the larger device. Finally, higher resolution 
photolithography techniques may be utilized to produce finer spacing in the pseudo-sieve 
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layer. This would permit even smaller droplets to be captured and analyzed in the trapping 
region. Incorporating this improvement may also lead to increased dynamic range and 
sensitivity of the platform. We hope that researchers may utilize this technique to develop 




Two photomasks were designed in L-Edit v16.0 (Tanner EDA, Wilsonville, OR, 
USA) for the upper chamber and for the pseudo-sieve post array and were printed onto 
high-quality transparency (CAD/Art Services, Bandon, OR, USA). To fabricate the molds, 
two silicon wafers were dehydrated for at least 6 hours, and oxygen-plasma treated at 85 W 
for 1 min (Technics PE-II, San Jose, CA, USA). For the upper chamber, SU-8 3050 
(MicroChem, Woburn, MA, USA) was spun at 3000 rpm for 30 s, baked at 65°C for 1 min 
and 95°C for 15 min, and exposed at 180 mJ/cm2. For the pseudo-sieve layer, the SU-8 
3025  (MicroChem, Woburn, MA, USA) was spun at 1800 rpm for 30 s, baked at 65°C for 
1 min and 95°C for 14 min, and then exposed at 175 mJ/cm2. Following exposure, both 
wafers were baked for 1 min at 65°C and 5 min at 95°C, developed with SU-8 developer, 
and baked at 200°C for 1 hr.  
The devices were fabricated from the master molds through soft lithography with 
30 g of PDMS (Ellsworth Adhesives, Germantown, WI, USA), mixed at a ratio of 10:1 
(w/w) with curing agent. The two layers were oxygen-plasma treated at 40 W for 45 s for 
bonding. A glass microscope slide (#26007, TedPella, Redding, CA, USA) and a 
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coverglass slip (#260340, TedPell, Redding, CA, USA) were then oxygen-plasma treated 
at 40 W for 45 s and bonded to the bottom and top of the device, respectively. The devices 
were baked overnight at 80°C, and desiccated for 2 hours. Prior to use, FC-40 oil was 
vacuum-loaded into the device. 
 
 Droplet Generation and ddPCR 
The aqueous phase was first drawn into a 100-cm-long section of Tygon tubing 
(#EW-06419-01, Cole-Parmer, Vernon Hills, IL, USA) with an inner diameter of 500 μm. 
The Tygon tubing section was then connected to a Hamilton 1000 glass syringe 
(SKU#20998, Sigma-Aldrich, St. Louis, MO, USA) containing FC-40 oil (SKU#F9755, 
Sigma-Aldrich, St. Louis, MO, USA), which served as the displacement fluid for injecting 
the aqueous phase into the device using a syringe pump (Harvard Apparatus, Holliston, 
MA, USA) at a flow rate of 640 μL/h. Droplet generation oil was injected into the device 
using a separate syringe pump at 2400 μL/h. Generated droplets were collected from the 
device’s outlet into a 1.5 mL DNA LoBind Tube (#022431021, Eppendorf, Hauppauge, 
NY, USA).  
Device loading was observed using a custom microscope with a 4 x objective lens 
(UPlanFl 4×/0.13 NA, Olympus, Tokyo, Japan) and a CMOS camera (#DCC1545M, 
ThorLabs, Newton, NJ, USA).  
 
 Image analysis 
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To perform droplet segmentation and identification, the first 10 images were loaded 
into ImageJ and averaged56. The resulting image underwent morphological opening, 
followed by a morphological segmentation of radius gradient 1 to segment and identify 
each droplet57. The droplet mask was then exported to Matlab for analysis along with the 
subsequent images. An automated script MATLAB (MathWorks, Natick, MA, USA) 
extracted the average raw fluorescence for each droplet at each temperature point and 
binned the values in 0.3°C intervals to generate a melt curve for each droplet. After 
Savitzky-Golay filtering of each curve, the negative derivative was taken to identify the 
peak, or melt temperature (Tm) of the droplet amplicon. The methylation density of the 























Figure 5.1. Droplet Trapping Device Architecture 
(A) The high-density trapping device may incorporate up to five modules as needed. Each 
module consists of a glass slide, PDMS sieve layer, and PDMS chamber layer with access 
ports. (B) A top view of the pseudo-sieve geometry shows the tightly spaced posts. Two 
highways run through each third of the device. (C) Droplets sit in the chamber above the 
posts. (D) Droplets are loaded until the chamber is full. Excess oil may pass through the 
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posts to the outlet. (E) Droplets are pressure loaded into the inlet, and self-assemble into a 
grid while loading. Droplets are trapped against the walls and immobilized. Since no 
droplets may escape, the device exhibits 100% loading efficiency. (F) The removal of 
excess oil removes wasted space between droplets, such that they may be packed in a high-





















Figure 5.2. Back-Pressure Relief 
(A) Droplets loaded into previous versions of the device (without highways) experience 
compression. Compression was most significant in the central lanes of the device. 
Snapshots are shown of the proximal and distal areas. (B) With highways to help spread 
the flow of droplets evenly, droplets remain uniform throughout the device and experience 
only minimal compression due to high-density packing. This figure is reprinted with 


















Figure 5.3. Fully loaded device with 500pL droplets 
Droplets were generated by flow-focusing, and underwent ddPCR in a BioRad C1000 
Touch Cycler. Droplets were then loaded into the trapping device with a syringe pump. 
Once, loaded, the device was sealed on both ends. Images were taken under an Olympus 
microscope with a 4X objective and stitched together using ImageJ. This figure is reprinted 
































Figure 5.4. CDO1 DREAMing with QX200 System 
Droplets were generated following the BioRad QX200 protocol containing target of 0%, 
50%, and 100% methylated CDO1 as well as a no-template control. The data was analyzed 
by BioRad QuantSoft software program. (A,B) The end-point fluorescent readout of the 
NTC was used to set a threshold of 12000. (C,D) The NTC threshold was used to identify 
the number of positive droplets for each target epiallele. (E) The concentration of each 
target was calculated by the number of events with BioRad QuantSoft. Each epiallele was 
repeated 8 times and showed very consistent results that closely matched the expected 


























Figure 5.5. Quantification Accuracy 
(A) Droplets were generated with target copies of bisulfite-converted methylated CDO1 at 
occupancies (λ) spanning 4 order of magnitude, from 0.04% to 11%. After PCR, the 
droplets were loaded into the trapping device and their fluorescence imaged with a wide-
field camera. Droplets were identified and counted in ImageJ. (B) The occupancy was 
calculated from the Poissonian occupancy based on the ratio of negative to total droplets 
and compared to the expected occupancy. The lower two and highest occupancies were 
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repeated twice. A linear fit was applied to the log-log curve of expected vs. calculated over 
the serial dilution. The slope of 0.98 is within 2% of the ideal slope of 1, and a R2 value of 








Figure 5.6. Size Versatility 
120 pL and 600 pL droplets were generated with our flow-focusing device. 1000 pL 
droplets were generated by the QX200 ddPCR system. Each droplet size underwent the 
same PCR protocol in a 96-well plate, and were subsequently loaded into the trapping 
device for imaging. Fluorescence images were acquired with the same wide-field camera 
and macro lens and the same working distance. Bright-field images were all acquired under 
an Olympus microscope at 4X magnification. All systems were compatible with the range 





Figure 5.7. High-Temperature Immobilization 
After loading, the device was sealed on both ends and placed on the thermal-optical system 
for real-time analysis. To demonstrate immobilization even at high, challenging 
temperatures, fluorescence images of the droplet capture region were acquired during 
thermal ramping from room temperature to 90°C, shown here in 5° intervals. A 
superimposed grid over a sub-region of the device pinpoints the position of each droplet 
from frame-to-frame. Droplets remain immobilized throughout in order to facilitate 














Figure 5.8. Image Processing and Droplet Segmentation 
Droplet segmentation was performed in ImageJ. The first ten fluorescent images were 
averaged together to increase the signal to background ratio. A morphological opening 
filter was applied to the resultant image using MorphoLibJ. Morphological segmentation 
then identified each droplet. A numeric label was assigned to each droplet, and a labeled 
mask was generated and exported to Matlab for quantification and melt curve analysis. 






























Figure 5.9. Droplet Digital High Resolution Melt 
(A) Fluorescence images of droplets containing amplicons of mixed epialleles were 
acquired during temperature ramping. Each epiallele denatures at distinct temperatures, 
measured as a loss of fluorescence of the dsDNA intercalating dye (Evagreen). (B) The 
average fluorescence of each droplet is plotted against temperature to obtain a melt curve. 
The negative derivation of the curve contains a peak, which is identified as the melt 
temperature (Tm) of the sequence. By identifying the Tm of each amplicon, a profile of the 
methylation heterogeneity within the sample may be obtained and analyzed. This figure is 











Figure 5.10. SNR and Fluorescence Leakage Analysis 
(A) Negative droplets surrounding the positive amplicons were identified to analyze the 
background signal. (B) The system demonstrates a signal-to-background of 1.9 at 80°C. 
(C) Closer inspection of background droplet fluorescence shows a slight decrease over the 
course of the experiment, indicating no decrease of the overall SNR and no observable 




























Figure 5.11. Droplet Generation Devices 
Two masks were designed for the high-density droplet packing device, including a (A) 
post layer mask, where polarity is positive, and a (B) chamber layer mask, where polarity 
is negative. (C) A flow-focusing droplet generator was used for generating 120 pL and 600 
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pL droplets. The nozzle width and channel height were custom-tuned in order to achieve 






ASSESSMENT OF BIOMARKER PANELS  
Diagnostic advantages of biomarker panel assessment 
Diagnostic tests for a given disease are scored by two metrics: (1) The percentage 
of positive test results from a truly positive sample set.  This is known as the “True 
Positive Rate” (TPR), and is also referred to as the sensitivity of a test or biomarker. (2) 
The percentage of positive test results from a negative or healthy sample set. This is known 
as the “False Positive Rate” (FPR), and is referred to as the specificity of an assay.  A 
perfect diagnostic test will score a perfect TPR of 1 and a perfect FPR of 0.  A TPR of less 
than 1 indicates that either test cannot detect low levels of a biomarker or that the particular 
biomarker is not present in all of the disease instances. A FPR be above zero indicates that 
the biomarker can also be found naturally in the healthy population. Most diagnostic tests 
are not ideal, in that there is some overlap between the cancerous and healthy populations. 
Thus, a threshold must be determined that defines both the TPR and FPR. To visualize the 
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performance of a test, researchers most often use what is known as the “Receiver 
Operating Characteristics” curve, a plot of 1-FPR vs. TPR. The area under the curve 
(AUC) determines the probability that a test with be able to distinguish between disease 
and healthy.  
Cancers express large amounts of both intra- and inter- tumor heterogeneity, 
leading most scientists to believe that pathogenesis may occur via a variety of different 
pathways. Thus when aiming for early detection, a single biomarker is likely to be 
insufficient for much of the population. Cancers have also been shown to express both 
epigenetic intra-tumor heterogeneity, that is epigenetic differences between patients, as 
well as inter-tumor heterogeneity, that is epigenetic differences within clones of a single 
tumor. For example, lung cancer exhibits significant genetic and epigenetic heterogeneity, 
which presents a challenge for development of a successful screening technique [160]. 
Several groups have investigated screening for lunch cancer methylation biomarkers in 
noninvasive bodily fluids such as plasma and sputum [161]–[163]; these studies have 
illustrated that detection of biomarker panels from at least 3-5 genes is required for 
clinically actionable sensitivity and specificity, although there is still room for 
improvement. Furthermore, studies have shown that early in carcinogenesis, but before 
malignancy, methylation levels may be highly variable in tumors levels [20], [30], [31]. 
This suggests that quantification of methylation variability within these panels may further 
improve diagnostic accuracy. 
Perhaps one factor contributing to the imperfect sensitivity of these techniques is 
the low levels of methylation in these fluids. Current technologies are ill-suited to quantify 
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methylation variability in complex solutions where the target molecules may be rare and 
infrequent. Sequencing, although comprehensive, is limited in sensitivity and is unpractical 
for routine use. Digital PCR technologies, such as droplet digital PCR, are limited to 
binary assessments of known target sequences, and thus are not suited for detection of 
variably modified loci. Thus there is a need for a more sensitive technique that can 
simultaneously assess a panel of methylation biomarkers.  
To satisfy the requirement for simultaneous biomarker assessment, some 
researchers have proposed spatial separation as a simple means to enable multiplex 
analysis with PCR-based methods, but this comes at a sacrifice of efficiency. Spatial 
separation inherently requires more reaction volume and therefore intrinsic waste, as only 
minor percentages of the sample input are interrogated for a single marker. Due to the 
scarcity of biomarkers in noninvasive fluids, this method is unsuitable for early detection 
of large panels of rare molecules in complex fluids such sputum and plasma. 
The most common and straightforward method of multiplex analysis within a 
single PCR-based assay is to use different color probes for each target. Typically, taq-man 
probes are used, which include a fluorophore and quencher at either end of a DNA 
sequence corresponding to its target, such that the fluorescence emission cannot be 
detected in its natural state. The probe anneals to its single-stranded DNA target sequence 
during the PCR reaction. As the Taq polymerase performs extension over that region, the 
probe sequence is cleaved, enabling the fluorescence emission to be detected.  
Single color-per-target multiplexing is limited by the spectral overlap of known 
fluorophores within the visible electromagnetic spectrum. Even with advanced optical 
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setups, typically this method is limited to the detection of 4-5 targets, which may not be 
sufficient for diagnostic confidence. In commercial digital PCR (dPCR) systems such as 
the BioRad QX200 and Fluidigm BioMark HD, only up to 2 or 3 fluorescent channels are 
available for detection.  
Several attempts have been made to expand the multiplexing capacity of digital 
PCR systems, but none are capable of simultaneous quantification of methylation 
heterogeneity. For example, several methods of multiplexing by detecting melt profiles of 
taq-man probes or molecular beacons have been proposed, but these methods require an 
abundance of single-stranded DNA, produced by asymmetric PCR, and thus are 
incompatible with intercalating dye-based HRM, which requires double-stranded DNA 
[125], [164], [165]. Alternatively, it has been proposed that using different concentrations 
of probe permits identification of different targets in the same color by detecting different 
fluorescent intensities, however this technique has only been demonstrated for detection of 
known sequences [66], [166].  
 Previously, we developed a facile molecule-by-molecule sequence analysis 
platform called HYPER-Melt [73]. Through digitization of single molecules into 
individual microchambers, methylation patterns could be interrogated by digital melt curve 
acquisition. This technique demonstrated very high sensitivity, 0.00005% 
methylated/unmethylated, but was limited to a single target locus. Herein, we expand this 
technique to simultaneously detect multiple target loci, thereby improving its potential 
clinical utility. 
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We present a methylation-agnostic ratiometric multiplexing scheme to enable high-
degree multiplexing of different targets as well as sequence profiling with HYPER-Melt 
within a single assay. This simple technique can be prepared as an all-in-one reaction, 
requires no additional reaction steps, and includes straightforward analysis. Methylation-
agnostic probes were developed to identify their loci independent of its methylation 
pattern. Bisulfite-converted sample was loaded into a microfluidic array to digitize each 
target locus (Figure 6.1A). Using a dual-fluorophore ratiometric analysis scheme enables a 
high-degree of multiplexing, which grows exponentially with each additional color (Figure 
6.1B). Finally, the methylation profile of each loci can be determined simultaneously 
through discrimination by HYPER-Melt (Figure 6.1C).  
 
Variable Sequence (Methylation-agnostic) Probe Scheme 
In order to identify a panel of loci with unknown methylation patterns, we first 
sought to overcome the challenge of designing probes specific to variable sequences. After 
bisulfite conversion, potential methylation sites in a sequence (CpG sites) may be either 
converted to uracil, replaced by thymine during PCR, or remain as a cytosine. Therefore, 
any sequence with n possible methylation sites may result in 2n sequences after bisulfite 
conversion. In many cases, finding a suitably long template without these variable sites is 
impossible, thus it is necessary to identify multiple patterns. 
To address this, we developed fluorescent probes with so-called “wobble bases” 
incorporated at each methylation-dependent base in the target locus (Figure 6.2). These 
“wobble bases” are equimolar mixtures of either cytosine or thymine. Ultimately this 
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results in equimolar probe amounts for each possible bisulfite-converted sequence. The 
resulting probe solution is thus “agnostic” to target epiallele methylation status, allowing 
its identification regardless of template methylation pattern. 
 
Ratiometric Multiplexing Scheme 
We next coupled this agnostic probe design to a ratiometric fluorescence 
multiplexing scheme to achieve a solution that provides high multiplexing capability while 
maintaining compatibility with dsDNA binding dyes, thereby allowing both simultaneous 
identification and HYPER-Melt analysis of many epiallelic gene targets (Figure 6.3A). For 
each target, two probes comprising identical sequences are designed but are differentially 
labeled with two different fluorophore-quencher pairs, such as yellow and red. This allows 
the probes to be mixed at a distinct red-to-yellow (R:Y) molar ratio to create a specific 
fluorescence signature for each target locus. Multiplexing can thus be achieved by 
assigning probe-pairs with a distinct R:Y ratio to target each of the genes in a panel (Figure 
6.3B).  
This technique is simple in analysis, as it only requires two-color detection, but 
scalable to high degrees of multiplexing. There is no fundamental limit to the number of 
ratios that can be designed, thus the actual limit of multiplex capacity per probe-pair will 
depend on the resolution and dynamic range of the detector. Furthermore, for each 
additional probe color, the multiplexing capacity of this system will increase exponentially.  
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Digital Ratiometric Multiplex PCR  
To perform an initial proof-of-concept of this technique, we selected three targets 
from a promising methylation biomarker panel for non-small cell lung cancer (NSCLC), 
HOXa7, TAC1, and SOX17, which has previously demonstrated an AUC of 0.89 and 0.77 
for lung cancer detection in sputum and plasma respectively [167]. Methylation-agnostic 
probes were designed for each locus. After experimental optimization of multiple 
fluorophores, HEX and ROX minor-groove-binding (MGB) probes were chosen for 
identification.  
We prepared reactions with different molar ratios of HEX and ROX probes for two 
targets, HOXa7 and TAC1, ranging from 4:0 ROX:HEX (R:H) to 0:4. Synthetic sequences 
representative of bisulfite-converted methylated and unmethylated HOXa7 and TAC1 were 
designed and purchased. Each probe ratio was assessed for detection of a single-copy of 
the respective methylated and unmethylated template sequences. End-point fluorescence 
was acquired using the default HEX and ROX channels of a BioRad CFX. After 
background subtraction, the end-point RFU for each fluorophore of each well was 
normalized to the RFU a calibration curve consisting of the 1:0 ratio of the respective 
probe.  
After calibration, the resulting molar ratios were calculated, which demonstrate 
excellent correlation with the expected probe ratio for each reaction (Figure 6.4). With this 
proof-of-concept, we demonstrate robust 5-plex detection by ratiometric probes with just 
two colors. Even though 5-plex detection may be sufficient for many biomarker panels, the 
technique is also readily scalable to higher degrees of multiplexing. 
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Microfluidic Digital N-plex Panel Identification 
Next we validated the use of different probe ratios for multiplex target 
identification in a highly parallelized microfluidic array. A single module of the 
microfluidic array consists of 10,000 nano-liter sized chambers arranged in a single-layer 
grid. A single device may hold up to 4 modules in parallel for high-throughput testing. The 
devices were fabricated via ultra-thin soft lithography, vacuum-loaded, and partitioned 
following our previously reported techniques [73].  
First, each target was interrogated independently among mixed probes to establish 
a reference standard. The devices underwent dPCR on a standard flatbed thermal cycler. 
Afterwards, the devices were imaged for end-point probe fluorescence by a typhoon 
scanner for two channels, Cy3 and Cy3-FRET. The negative wells for each device served 
as the background, and were used to correct for any module-to-module variability and for 
normalization of the positive wells.  
A grid mask was mapped to the resultant fluorescence image to identify each well. 
A semi-automated program using four-corner selection was utilized to perform a 
homography transformation to align the mask to the image, as we have described 
previously [73]. Due to the intrinsic warping that occurs during soft lithography, this 
technique initially resulted in many wells with poor alignment. To address this, an 
interpolative algorithm was developed to predict the variable warping across the device. 
The vectorized fluorescent gradient for each predicted well position was acquired, and 
used for a two-step warping correction in both the horizontal and vertical directions. For 
138 
correction in the vertical direction, the vectorized y-gradient of each row was averaged and 
plotted against horizontal row number. A 4th-degree polynomial was fit to these points and 
the roots identified. Each row of wells was then translated up or down depending on the 
calculated magnitude of the average gradient at that point. Finally, neighborhood 
optimization was then used to correct for any nonlinear warping effects.  
The central pixels of each well were averaged together to provide the end-point 
RFU per well.  This process was repeated for the second fluorescence image. To determine 
if either the HEX or ROX channel were susceptible to spectral overlap from the 
intercalating dye (Evagreen), reactions were prepared with and without Evagreen and 
imaged under both probe channels after amplification. Neither channel appeared to exhibit 
nonspecific fluorescence emission from the Evagreen intercalating dye (Figure 6.5A).  
Finally, ROX RFU vs. HEX RFU scatterplots were generated to determine the confidence 
bounds of each probe ratio (Figure 6.5B). Each probe ratio is distinct and without overlap.  
Next, mixed target loci were digitized in a single module with probe ratios of 1:3 
for TAC1 and 5:1 for HOXa7. Following dPCR, the module was imaged under HEX and 
ROX fluorescent channels, and the probe ratio for each amplicon was calculated. 
Comparison of the mixed loci demonstrates excellent agreement with the individually 
acquired probe results, validating the proof-of-principle that this method is suitable for 
multiplex identification (Figure 6.5B).  
 
Microfluidic Digital N-plex assessment of methylation heterogeneity 
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Besides having a high degree of multiplexing capacity, the distinct advantage of 
this ratiometric probe technique is its compatibility with HYPER-Melt discrimination of 
locus-specific epialleles. After amplification, the device is placed on a thermal-optical 
platform for simultaneous melt curve acquisition from each amplicon as described 
previously [73]. Briefly, fluorescent images are acquired at 0.3°C temperature intervals 
from 75°C to 95°C. The average fluorescence of each well is extracted and plotted against 
temperature to produce a melt curve. The negative derivation of this curve contains a peak, 
which defines the melt temperature (Tm) of the template molecule. This Tm correlates 
with the original methylation density of the locus. For each amplicon, aggregating the Tm-
methylation pattern and the probe-ratio-ID thereby enables methylation profiling for 
multiple targets.  
To validate the performance of this device, synthetic sequences representative of 
bisulfite-converted fully methylated epialleles of two loci, HOXa7 and TAC1, were 
synthesized and assessed. Each epiallele was digitized in the microfluidic array and 
amplified. Following amplification, melt curves were acquired for each amplicon, and a 
Tm histogram depicts the methylation profile of each sample (Figure 6.5C). The template 
methylation pattern of each amplicon can readily be identified by thresholding. The 
platform demonstrates high melt temperature uniformity for each epiallele.   
 
Discussion 
The report represents the first platform to demonstrate digital multiplexed 
molecule-by-molecule analysis of methylation heterogeneity. This platform enables 
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parallelized in-depth analysis into the mechanisms of two well-established phenomena of 
early disease progression: increasing epigenetic variability as well as the accumulation of 
aberrant regulation among several loci. Studying the methylation heterogeneity of multiple 
loci in parallel can provide greater insights into disease progression as well as increase the 
fidelity of molecular diagnostic techniques. 
Genetic and epigenetic variability is an integral part of disease progression [1], 
[16]. Several models have predicted that increasing variability in DNA methylation occurs 
in precursor regions, before the onset of disease [29], [30], [110], [168]. The precise effects 
of this variability are only just beginning to be scrutinized. The paucity of current studies 
may be due to insufficient technology for quantitative, multidimensional analysis. 
Assessment of methylation heterogeneity of rare molecules is challenging and 
unpractical with current commercial techniques. Targeted bisulfite sequencing could detect 
variability of multiple loci, however its high cost and complexity are often deterrents. 
Furthermore, its limited sensitivity would restrict its use to abundant samples such as tissue 
biopsies, which is ill-suited towards early detection of disease. A simpler, more sensitive 
technology that is becoming routine in research laboratories is ddPCR. However, detection 
of variable sequences with ddPCR would require probes for each sequence. Although 
feasible, each assay would be complex, and each variable-sequence probe would reduce 
the capability for multiplex analysis of different loci. 
The ultimate goal of this work is to facilitate early detection of disease. Due to the 
myriad of possible tumorigenesis pathways and heterogeneity of disease, a single 
biomarker is unlikely to provide diagnostic utility in a large population. Especially in early 
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phases of disease, before malignancy, a diagnostic panel should assess the regulation of 
several pathways, as natural redundancies require several pathways to be disrupted before 
malignancy [169]. However, multiplex biomarker detection of rare molecules is 
challenging.  
In noninvasive sampling techniques, such as plasma or cell-free DNA, tumor-
derived molecules can be very infrequent, requiring larger than usual volumes of sample to 
be collected in order to capture these molecules. In such a case, the efficient use of the 
sample is critical to ensure that biomarkers are not excluded from analysis. Multiplex 
techniques that require physical partitioning of the sample are susceptible to lost 
information due to inefficient interrogation of the entire sample. The microfluidic 
multiplex digital melt platform presented here uses ratiometric probes to overcome that 
hurdle, enabling sensitive interrogation of all designated biomarkers. 
Recent studies have shown promising results using methylation as a biomarker for 
early-stage NSCLC [161]–[163]. Our platform offers orders of magnitude higher 
sensitivity over traditional techniques as well as multidimensional analysis of n-plex gene 
panels. Ultimately, we hope that the capabilities of this platform manifest in improved 






















Figure 6.1. Overview of Multiplex HYPER-Melt Profiling 
Bisulfite-converted DNA is loaded into the device and the fragmented DNA is digitized 
into microchambers (A). (B) For each target, probes with two fluorophores are mixed in 
distinct ratios to identify the locus. (C) After ratiometric probe-based identification, the 






Figure 6.2. Methylation-agnostic probes 
After bisulfite conversion, many possible sequences exist per locus. Wobble bases at 








Figure 6.3. Highly multiplexed ratiometric probe scheme 
For each target a distinct ratio of Yellow:Red probes are prepared (A), enabling high 






Figure 6.4. Ratiometric Identification principle 
Five different ratios were prepared for each of two targets to demonstrate the ratiometric 
principle of identification. The calculated ratios closely match the target ratio, and cluster 




Figure 6.5. Simultaneous Locus Identification and Profiling 
(A) Targets were digitized in the microfluidic device. In the first module, only Evagreen 
intercalating dye was used. In the second module, evagreen and specific probes were 
combined. The images of Cy3 and Cy3Fret channels demonstrate negligible background 
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fluorescence overlap with the Evagreen dye. (B) Two targets were digitized at differing 
fluorescence ratios, first separately, and then combined. The calculated ratio of the 
multitarget assay matches that of the references. (C) Melt curves acquired from the two 





Figure 6.6. 4-Color Imaging Platform 
An optical platform was designed to accommodate four non-interfering fluorophores for 
multiplexed identification. The optimal fluorophores were determined to be Evagreen, 







ANALYSIS OF METHYLATION HETEROGENEITY 
IN COMPLEX SAMPLES 
Challenges and Advances in screening techniques 
For almost all cancers, earlier detection leads to a higher chance of survival. To this 
end, routine screening is highly recommended for cancers that can be detected early, 
before symptoms arise. For example, the 5-year survival rate of colorectal cancer is 90% 
when detected in early stages [170]. However, this rate drops to 15-70% if the cancer is 
diagnosed at a later stage when the cancer has started to spread.  
The most sensitive screening test for colorectal cancer is an optical colonoscopy, 
which detects 95% of colorectal cancers [171]. The US Preventative Services Task Force 
(USPSTF) recommends that persons over age 50 receive a colonoscopy every 5-10 years. 
However, adherence to this screening method is hindered by the invasiveness of the 
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procedure, timeliness, and cost. To address this, many other noninvasive screening 
methods for colorectal cancer have been proposed and analyzed [171].  
Two of the most prominent noninvasive screening tests are the Fecal 
Immunochemical Test (FIT) and multi-target testing [171], [172]. Both methods involve 
detection of proteins or genetic and epigenetic markers in noninvasive fluid samples. The 
multi-target testing, now marketed as Cologuard ®, includes two methylation biomarkers 
[172]. Such a noninvasive screening method could encourage stronger adherence to routine 
screening, and, if positive, could serve as an early warning that warrants further tests, such 
as a colonoscopy. Therefore, there is a need for sensitive technologies to detect rare 
biomarkers within noninvasive fluids to facilitate routine screening.  
One noninvasively collectable sample media that traverses the most surface area 
and through most other tissues throughout the body is blood. Recently, it has been 
discovered that all cells release cell-free DNA into the plasma, which retains the 
characteristics of its source tissue [33]–[35], [42], [173]. Since then, there has been an 
explosion of research into identifying biomarkers in the blood plasma for many types of 
cancer, including colorectal cancer [92], [173]–[177]. Of the promising biomarkers that 
have been identified, many include hypermethylated regions of DNA such as tumor 
suppressor genes [17], [56], [175]–[181]. We believe that the HYPER-Melt technology 
could offer improved sensitivity over current techniques. Therefore, we sought to validate 
the HYPER-Melt technology in complex biological fluids to assess its potential utility for 
early detection and screening. 
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Methylation heterogeneity in plasma samples from liquid biopsy 
We sought to demonstrate the potential clinical utility of the platform by employing 
HYPER-Melt for the analysis of methylation heterogeneity of a cfDNA biomarker of 
colorectal cancer (CRC) from liquid biopsies of cancer-free volunteers compared with 
patients diagnosed with metastatic CRC (mCRC).We chose to interrogate the methylation 
patterns of N-Myc downstream-regulated gene 4 (NDRG4), which has been implicated in 
neurite outgrowth and cellular differentiation via the regulation of transcription  factors 
[182], and whose in-tissue clinical sensitivity for CRC is 86% [183], [184]. DREAMing 
primers for NDRG4 were designed and optimized to achieve single-copy sensitivity, as 
previously described [63]. 
cfDNA from the blood of four cancer-positive patients and four ostensibly healthy 
volunteers was extracted, purified and underwent bisulfite conversion (Figure 7.1), as 
detailed elsewhere [63]. Each sample was amplified, melted, and analyzed using the same 
protocol as described previously [73]. Methylation patterns from each sample are found in 
Figure 7.2. For comparison, each sample was also assessed for NDRG4 methylation using 
quantitative methylation specific PCR (qMSP) [49], [50]. Of the four CRC-positive 
patients, three of four were clearly positive for NDRG4 methylation by HYPER-Melt, only 
one of which showed clear positivity with the NDRG4 qMSP assay (Figure 7.3). 
Interestingly, of the four samples from healthy volunteers, one was positive for NDRG4 
methylation by HYPER-Melt, albeit at very low levels of low to intermediate methylation.  
From these data, it is readily apparent that HYPER-Melt exhibits both considerably 
higher analytical sensitivity when compared to qMSP. This is not unexpected, as MSP is 
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designed to ostensibly only detect fully or very heavily methylated epialleles. In practice, 
however, most MSP-based assays can still amplify heterogeneously-methylated epialleles, 
albeit at much lower sensitivity and efficiency. Hence, samples such as CRC 1, that exhibit 
significant copy numbers of low and medium-density methylation by HYPER-Melt, 
exhibit weak, non-quantitative positivity by qMSP [185]. In all, HYPER-Melt 
demonstrated 20-300X or more analytical sensitivity than the qMSP assay in all 
methylation-positive samples. The greater analytical sensitivity of HYPER-Melt resulted 
in detection of NDRG4 methylation in two additional CRC-positive patients (CRC1 and 
CRC2) that are negative or nearly negative by qMSP.  While clearly beneficial in the case 
of the CRC-positive patients, HYPER-Melt also detected methylation in one of the healthy 
controls. The presence of very low copy numbers of heterogeneously-methylated NDRG4 
epialleles in sample N1, a 50-year-old male, may be due to natural methylation 
heterogeneity resulting from early-stage epigenetic drift [110]. 
In terms of potential clinical use, one of the highly-touted advantages of liquid 
biopsies is the ability to ostensibly sample overall tumor heterogeneity using a simple 
blood draw. However, the extremely low copy numbers of circulating tumor DNA 
(ctDNA) within the overall cfDNA samples, make assessment of this heterogeneity 
extremely challenging. As a proof of concept, the potential power of our platform was 
demonstrated by using such liquid biopsy samples. Overall, the considerable dynamic 
range of the platform allowed ultra-sensitive detection of heterogeneous NDRG4 epialleles 
down to 1 in 2 million unmethylated epialleles and in clinical plasma samples at 
concentrations of less than 150 copies per mL of plasma. HYPER-Melt also demonstrates 
robustness against multiple samples and targets, providing more information about cfDNA 
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epiallelic fractions than either MSP or traditional DREAMing while achieving over 100-
fold greater sensitivity.  
 
Challenges and Advances in Ovarian Cancer Screening 
The most common form of ovarian cancer is high-grade serous carcinoma 
(HGSOC), which accounts for about ¾ of all ovarian cancers [186], [187]. HGSOC is very 
aggressive and most often diagnosed in the advanced stages, which may contribute to the 
low survival rate of 31% [186], [188], [189]. Ultrasound analysis in conjunction with 
detection of the protein CA-125 has been investigated as a biomarker for early cancer 
detection; however, the poor specificity of the test resulted in no increased survival 
probability from screening [188]. Therefore, the USPSTF recommends against this 
screening method, hence there is currently no screening method available.  
In recent studies on the etiology of HGSOC, it has been shown that most 
carcinomas originate in the fallopian tube as serous tubal intraepithelial carcinomas 
(STICs) [187], [190]–[192]. However, unlike cancers arising in readily accessible tissues, 
such as the colon, breast, cervix, and lung, which are amenable to biopsy screening, the 
fallopian tubes and ovaries are not readily accessible for screening by optical or biopsy 
methods. The high mortality and incidence rate of this disease have thus prompted many 
investigations into molecular biomarkers for ovarian and other gynecological cancers. 
Cellular migration from the ovary to the uterus is a naturally occurring process 
during ovulation. Observations of routine Pap specimens have shown that some women 
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present with abnormal glandular cells. Of these abnormal specimens, more than a third 
were also shown to have pre-invasive disease as well as invasive carcinomas of nearby 
tissues such as the ovary, endometrium, and cervix [193]. This has led investigators to 
hypothesize that tumor-derived cells or DNA could be found in the cells and cervical-
vaginal fluid routinely collected in a Pap specimen. 
Recently, a new deep sequencing method called “PapSEEK” has been used to 
interrogate DNA in Pap specimens for mutations specific to ovarian and endometrial 
cancer [194], [195]. Using a mutation panel, researchers were able to identify tumor-
specific mutations in 33-45% of ovarian cancer specimens and 81-93% of endometrial 
cancers with extremely high sensitivity (>99%) in late stage as well as early stage disease 
[194], [195]. These promising results indicate routine Pap specimen analysis could be a 
new avenue for ovarian cancer detection and screening. 
Despite the exciting results, the sensitivity toward ovarian cancer remains low, and 
could benefit from more sensitive detection techniques or biomarkers. Tumor-derived or 
STIC-derived cells in Pap specimens may be eclipsed by the high background from healthy 
epithelia, necessitating an extremely sensitive detection technique. Furthermore, many 
studies have investigated the utility of methylation biomarkers for ovarian cancer detection 
[196]–[200], and have found much higher prevalence of hypermethylation in tumor 
suppressor gene panels, even up to 90% sensitivity and 100% specificity in limited cohorts 
[201]. Recent studies indicate that locus-specific hypermethylation can be identified in 
HGSOC precursor lesions, STICs [202], indicating the potential for early detection. 
Moreover, variable methylation could be an even earlier indication of disease 
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gynecological disease [30], and epigenetic reprogramming is an integral part of ovarian 
cancer progression [203].  
 To this end, we applied the HYPER-Melt platform for detection of rare methylated 
epialleles in DNA acquired from Pap specimens. We identified target loci that were 
previously reported to demonstrate 100% specificity towards ovarian cancer tissue in a 
methylation EPIC BeadArray cohort [204]. DREAMing assays were developed for the top 
performing loci. Finally, the assays were validated on the HYPER-Melt platform, and the 
clinical utility was validated with Pap specimens from both ovarian cancer and healthy 
patients, outperforming the gold standard, MSP, in diagnostic performance.  
 
Methylation heterogeneity in Pap Specimens 
To identify promising target loci, our collaborators previously performed genome-
wide methylation analysis of ovarian cancer using the latest-generation Methylation EPIC 
BeadArray platform in a cohort of 60 malignant and 36 healthy gynecological mucosal 
samples [202]. After selecting for 100% specificity, DREAMing assays were developed 
for the top performing loci and validated for detection of ovarian cancer in a 90-patient 
tissue cohort, demonstrating 100% sensitivity and specificity. Furthermore, methylation 
within these loci were detectable in 9 of 9 laser capture microdissected (LCM) ovarian 
cancer precursor serous tubal intraepithelial carcinoma (STIC) lesions and 0 of 12 LCM 
cancer-free fallopian tube, suggesting that they are very early events in HGSOC 
development.  
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As a proof-of-concept for this project, we developed a DREAMing as well as a 
qMSP assay for IRX2, one of the top performing biomarkers in our initial panel. The 
DREAMing assay was validated on the HYPER-Melt platform. The platform itself was 
expanded to accommodate high-throughput sample analysis. Each device consisted of 3 
modules, each containing 20,000 1 nanoliter-sized microchambers. Sample preparation, 
loading, dPCR and dHRM procedures followed those in our previous report [73].  
To validate the robustness of the platform to DNA extracted from Pap specimens, 
we analyzed the methylation heterogeneity of IRX2 in 3 specimens from HGSOC patients 
and 6 specimens from matched healthy patients. Heterogeneously methylated DNA was 
detected and quantified in all of the ovarian cancer patients (Figure 7.4). DNA from the 
healthy patients was also detected and the patterns identified on the HYPER-Melt 
platform. To assess the potential clinical utility of the system, we compared the normalized 
amount of highly methylated DNA per µL for each sample. The HYPER-Melt platform 
detected overall higher amounts of methylated DNA in the cancer specimens than the 
healthy for all samples (Figure 7.5). By setting a threshold of 8 copies/ µL, the results 
demonstrate 100% sensitivity and 100% specificity. 
The samples were also asses by the gold standard, qMSP, for fully methylated 
epialleles. Comparing the results from the two platforms, qMSP identified 1 of 3 samples 
as positive, and was negative for all of the healthy samples, resulting in 33% sensitivity 
and 100% specificity (Figure 7.5). The HYPER-Melt platform clearly demonstrates higher 
sensitivity and more comprehensive analysis than qMSP. These results suggest that 
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utilization of the HYPER-Melt platform with Pap specimens could greatly improve 
diagnostic performance over traditional techniques.  
Although promising, these results are from a limited sample cohort. Further 
assessment of the HYPER-Melt platform towards detection of HGSOC from Pap specimen 
methylation markers is ongoing with a larger patient cohort. The results presented here 
include data from only one epigenetic marker. If the specificity or sensitivity is challenged 
in the larger cohort, additional markers could readily be interrogated in the platform to 
improve clinical performance. Furthermore, the feature-space available within the 
HYPER-Melt datasets is only just beginning to be explored. Future work may uncover new 




All blood samples from patients diagnosed with metastatic colorectal cancer 
(mCRC) were obtained through a study with approval by the MD Anderson Institutional 
Review Board, and all participants provided written informed consent (NCT01730586). 
Blood samples were collected at baseline from mCRC patients prior to clinical trial 
treatment. Blood samples of cancer-free individuals were obtained from outpatients of 
Johns Hopkins Community Physicians, with approval by the Johns Hopkins Medicine 
Institutional Review Board. All participants provided written informed consent. mCRC 
and cancer-free patient characteristics are provided in Figure 7.1. All blood samples were 
collected in Cell Preparation Tubes (BD, Franklin Lakes, NJ) and processed within one 
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hour with centrifugation (3000 g) for 30 minutes and then plasma was aliquoted to 1.8 mL 
cryovials and stored at -80°C until analysis.  
All cfDNA was extracted using 2 ml NeoGeneStar Circulating Cell Free DNA Kit 
(NeoGeneStar, Somerset, NJ) according to the manufacturer’s instructions. Briefly, 2.0 mL 
of plasma was stabilized with Pretreatment Buffer and then digested in a solution 
containing 1X Protease Buffer and 100 µl of Proteinase K (Invitrogen). DNA was then 
extracted with supplied chaotropic salts and washed by a series of magnetic decantation 
steps and eluted into 20 µl of DNA elution buffer (Zymo Research, Irvine, CA). Extracted 
cfDNA was quantified by quantitative PCR (qPCR) using primers recognizing β-Globin, 
Forward Primer: 5’- TGA AGG CTC ATG GCA AGA AAG – 3’, Reverse Primer: 5’ – 
GAG GTT GTC CAG GTG AGC CA – 3’. PCR performed using 10X PCR Buffer 
(ThermoFisher Scientific) to yield a final volume of 25 µl and final working concentration 
3.5mM MgCl2, 200µM of each deoxynucleotide triphosphate (dNTP) and 0.04 U/µl of 
Platinum Taq polymerase (ThermoFisher Scientific).  Cycling conditions were 95˚C for 5 
minutes, followed by 50 cycles of (95˚C for 5 seconds, 65˚C for 30 seconds and 72˚C for 
30 seconds). Standards for quantification were created by serial dilution of human male 
genomic DNA (Promega). The resulting DNA was bisulfite converted using the EZ DNA 
Methylation-Lightning Kit (Zymo Research) according to the manufacturer’s protocol and 
eluted into a final volume of 12 µL. Final BST-cfDNA yields were quantified by β-Actin 
PCR, as described for control DNA above. 
Pap Specimens 
Pap specimens were collected by collaborators at Johns Hopkins hospital. The 
specimens were fixated in methanol upon collection. DNA was extracted from the cell 
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pellet following the NeoGeneStar extraction kit protocol. Next, the samples were bisulfite-
converted using the EZ DNA Methylation-Lightning Kit (Zymo Research) according to the 
manufacturer’s protocol and eluted into a final volume of 25 µL. 1-2 µL were used for 






Figure 7.1. Clinical Sample Workflow and Patient Characteristics  
(A) Workflow from sample collection to HYPER-Melt analysis. (B) Biological 
information for each patient from whom plasma samples were extracted and analyzed. The 
plasma volume for each sample collected was 2 mL. Concentration was estimated from 

























Figure 7.2. NDRG4 Copies Detected in Plasma Samples 
HYPER-Melt was performed on plasma from colorectal cancer patients and normal/ 
healthy samples for the NDRG4 gene. The methylation density of each molecule was 
classified by melt temperature. (A, B) HYPER-Melt heatmaps and heterogeneity analysis 
163 
of copies detected from plasma of colorectal patients (D, E) as wells as healthy volunteers. 




Figure 7.3. Liquid Biopsy (cell-free DNA) biomarker detection and analysis via 
HYPER-Melt. 
 Methylation data acquired for the NDRG4 locus from DNA extracted from plasma 
samples from both metastatic colorectal cancer and normal patients. (A) Three different 
levels of methylation density (Low, Medium, Heavy) were identified for each patient via 
the HYPER-Melt platform. The total number of methylated epialleles detected from each 
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patient sample was compared to that of the gold standard, MSP. HYPER-Melt histograms 
show the number of copies detected at each epiallelic fraction from plasma from (B) CRC 






Figure 7.4. Methylation Heterogeneity in Pap specimens 
DNA was extracted from Pap specimens, bisulfite-converted, and interrogated for 
methylation heterogeneity of IRX2 on the HYPER-Melt platform. Various levels of DNA 






Figure 7.5. Methylated IRX2 in Cancer and Healthy Patients 
The amount of heavily methylated DNA in copies/µL was calculated for all patients. 
Setting a threshold of 8 copies/µL produces 100% sensitivity and 100% specificity. 







This dissertation describes the development of a digital microfluidic platform that 
performs ultra-sensitive intramolecular profiling through highly parallelized real-time 
analyses. Accessibility and facile operation were key design criteria for this platform, 
which were incorporated through use of a single-layer microarray design coupled with a 
simple ultra-thin fabrication protocol. The device can be rapidly loaded and digitized by 
surface-tension, a facile and scalable method. I demonstrated that this platform, termed 
HYPER-Melt (High-density Profiling and Enumeration by Melt) is capable of quantifying 
locus-specific methylation heterogeneity and detection of rare epialleles at fractions as low 
as 1 in 2,000,000 background molecules, or 0.00005%.  
The capabilities of the HYPER-Melt platform were then expanded by increasing 
the efficiency of target capture as well as the sample throughput. Geometric manipulation 
of the fluid in a multilayer device improved loading efficiency to 80%. This dissertation 
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also reports the first demonstration of droplet digital high-resolution melt. I invented a 
microfluidic pseudo-sieve that achieved 100% efficiency in droplet loading and 
immobilization of droplets during high-temperature melt analysis. This device can be used 
in combination with commercial droplet techniques to greatly increase the throughput of 
epiallelic profiling. Finally, this platform demonstrated robustness towards complex 
clinical fluids. The HYPER-Melt platform achieved higher sensitivity and more 
comprehensive analysis in detecting methylation than the gold standard, MSP, in cell-free 
DNA in plasma as well as with DNA extracted from Pap specimens. 
This platform is ideally suited towards applications that require real-time 
monitoring to identify rare variants, such as circulating biomarker detection, bacterial 
persistence, antibiotic susceptibility, drug discovery, and directed evolution. Here, the 
HYPER-Melt platform was applied to the assessment of methylation heterogeneity, a 
phenomena that occurs early in carcinogenesis but is not yet fully understood. The system 
resolved methylation differences of 4 CpGs within a locus. Recent studies suggest that 
changes at this level may have a significant effect on cancer progression. The principle 
advantages of this platform over current technologies are the high sensitivity for detection 
of rare molecules, and the simple, economic ability to profile variable sequence patterns. 
Sequencing remains the most suitable technology for comparing sequence variability in 
abundant starting material, whereas ddPCR has the fundamentally highest sensitivity 
towards ultra-rare detection. HYPER-Melt represents a facile profiling technique that 
combines ultra-high sensitivity with locus-specific sequencing capabilities, designed to be 
applied towards methylation profiling of a limited number of loci within samples 
containing scarce or rare biomarkers. 
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Future work could include efforts to increase the throughput of the device as well 
as relaxing the device storage requirements. Despite the demonstrated improvements in 
throughput, the current system is limited in practicality to assessment of 10-20 samples per 
day. This restriction limits its utility towards assessment of large patient cohorts. 
Improvements to the optical resolution and thermal uniformity of the platform may 
increase the capability of the platform to assess hundreds of samples per day, which would 
much be more attractive for clinical utility. In addition, the current loading method requires 
the device to be kept under vacuum, which mandates a limited timeframe between 
atmospheric exposure and loading. Eliminating the need for a vacuum could make the 
system more robust to a wider variety of users. Such improvements would facilitate more 
widespread adoption of this technology. 
The ultimate long-term goal of this platform is to facilitate early cancer detection 
through screening for biomarkers in noninvasive fluids. Therefore, future studies should 
assess large patient cohorts to identify suitable biomarkers or biomarker panels within 
these fluids. Currently, efforts are ongoing to determine its potential for detection of lung 
cancer markers in plasma as well as ovarian cancer markers in Pap specimens. Biostatistic 
analytical tools should be developed to take advantage of the comprehensive datasets 
provided by the HYPER-Melt platform.  
In conclusion, HYPER-Melt provides an all-in-one platform for quantitative 
molecular profiling and heterogeneity analysis. The platform allows deep insight at the 
single copy level of any target of interest. Furthermore, the practicality and high 
digitization power of the platform offers a tool for rapid and efficient DNA sequence 
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heterogeneity analysis by rapidly interrogating hundreds to thousands of individual 
molecules in parallel. Overall, this platform has the potential to detect intermolecular 
variability at ultra-high sensitivity even in difficult and highly-heterogeneous samples, 
allowing more comprehensive investigation of the dynamics and stochasticity of DNA 
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